ࡱ> [ rbjbj1[1[ S1\S1\m**77777T777|8X9,7Lj&:;Xp;p;p;v=T?4?FHHHHHH$l7?T="v=??l77p;p;,F,F,F?7p;7p;F,F?F,F,FZVp;`2@&@ބ20Lj?A2?V?7V,F???llC2???Lj??????????????*> V6: Inhalant Abuse  Compiled by Tamara Espejo, RN, MS 4.0 Contact Hours California Board of Registered Nursing CEP#15122 Key Medical Resources, Inc. 6896 Song Sparrow Rd, Eastvale, CA 92880 951 520-3116 FAX: 951 739-0378 Disclaimer: This packet is intended to provide information and is not a substitute for any facility policies or procedures or in-class training. Legal information provided here is for information only and is not intended to provide legal advice. Each state or facility may have different training requirements or regulations. Participants who practice the techniques do so voluntarily. Information has been compiled from various internet sources as indicated at the end of the packet. Title: INHALATION ABUSE 4.0 C0NTACT HOURS CEP #15122 70% is Passing Score Please note that C.N.A.s cannot receive continuing education hours for home study. Key Medical Resources, Inc. 6896 Song Sparrow Rd., Corona, CA 92880 Please print or type all information. Complete answers and return answer sheet with evaluation form via fax or email to Key Medical Resources, Inc. Email:  HYPERLINK "mailto:Educate100@aol.com" Educate100@aol.com FAX: 951 739-0378 Name: ________________________________ Date Completed: ______________ Score____ Email:_____________________________ Cell Phone: ( ) ______________ Certificate will be emailed to you. Address: _________________________________ City: _________________ Zip: _______ License # & Type: (i.e. RN 555555) _________________Place of Employment: ____________ Please place your answers on this form. . _____ _____ _____ _____ _____ _____ _____ _____ _____ _____ _____ _____ _____ _____ _____ _____ _____ _____ _____ _____ _____ _____ _____ _____ _____ My Signature indicates that I have completed this module on my own._____________________ (Signature) EVALUATION FORM Poor Excellent 1. The content of this program was: 1 2 3 4 5 6 7 8 9 10 2. The program was easy to understand: 1 2 3 4 5 6 7 8 9 10 3. The objectives were clear: 1 2 3 4 5 6 7 8 9 10 4. This program applies to my work: 1 2 3 4 5 6 7 8 9 10 5. I learned something from this course: 1 2 3 4 5 6 7 8 9 10 6. Would you recommend this program to others? Yes No 7. The cost of this program was: High OK Low Other Comments: Title: INHALATION ABUSE Self Study Module 4.0 C0NTACT HOURS Choose the Single Best Answer for the Following Questions and Place Answers on Form: 1. Products commonly abused by inhaling include all of the following except: A. Lighter fluid, gas, butane B. Paint, air fresheners, laughing gas C. Asthma inhalers, nail polish, hair spray D. Oxygen, ipecac, epinephrine 2. The appeal of using inhalants includes: A. Longer onset of effect B. More challenging to obtain C. Status because of rising cost D. Quality and pattern of the high 3. Characteristics of youths likely to start using are: A. Emotionally stable B. Resistant to peer pressure C. Supportive family D. Risk taker 4. The process of inhaling vapors from an open container is called: A. Huffing B. Sniffing C. Spraying D. Bagging 5. The term for groups of inhalant abusers, most likely to be involved in serious legal offenses, is: A. Transient social B. Transient isolate C. Chronic isolate D. Chronic social 6. Inhalants are absorbed into the blood from the alveoli. A. True B. False 7. Signs of inhalant abuse include all of the following except: A. Constantly smelling B. Clothingsleeves C. Increased appetite D. Red or runny eyes and nose E. Sores around the mouth 8. Inhalant intoxication can develop within: A. 5 minutes B. 10 minutes C. 15 minutes D. 20 minutes 9. "Tolerance" means that inhalers can use less frequently and in lesser amounts to get the same effect. A. True B. False 10. Cardiovascular effects from inhalant usage include: A. Vasoconstriction B. Bradycardia C. Cardiomyopathy D. Pharyngitis 11. A diagnostic evaluation of an inhalant abuser should include all of the following except: A. ECG B. Neuropsychologic testing C. Bone scan D. MRI 12. A routine drug screen can detect inhalant usage. A. True B. False 13. Asphyxiation from inhaling is caused from displacement of available oxygen in the lungs. A. True B. False 14. "Sudden Sniffing Death" can occur the first time someone uses inhalants. A. True B. False 15. Long term consequences of inhaling include: A. Suicide B. Choking C. Suffocation D. Dementia 16. Guidelines for parents trying to prevent their children from using inhalants include having children do as they are told rather than making their own judgments and fostering independence. A. True B. False 17. According to the American Academy of Pediatrics website, the following steps can help prevent your child from turning to inhalants, EXCEPT: A. Set a good example at home B. Help your child develop different interests C. Help your child resist peer pressure D. Do not talk about drugs with your child E. Build self-esteem and confidence. 18. Inhalant abuse is the 4th most common form of drug abuse by adolescents. A. True B. False 19. Sudden sniffing death occurs when sniffing household products stops oxygen from reaching the brain and other organs. A. True B. False 20. Inhalants are substances whose vapors can be inhaled to produce a mind-altering effect. A. True B. False 21. Death from inhalant abuse can occur after a single use or after prolonged use. A. True B. False 22. Users may also inhale from balloons filled with nitrous oxide or other devices such as snappers and poppers in which inhalants are sold. A. True B. False 23. Inhalants combined with alcohol, sleeping pills, or other illicit drugs decrease the risk of death. A. True B. False 24. Inhalant abusers may spray chemicals into plastic bags or onto rags and hold them over their mouth and nose, causing skin breakdown. A. True B. False 25. Detoxification can take up to 40 days after which the patient will be completely cured. A. True B. False Title: Inhalant Abuse Self Study Module 4.0 C0NTACT HOURS Please note that C.N.A.s in California cannot receive continuing education hours for home study. Objectives At the completion of this program, the learners will: Define inhalants Identify classes and examples of inhalants Recognize reasons why youths are using inhalants Acknowledge inhalant practices by gender and ethnicity State methods of inhalation and the most frequent site of usage Explain the effects of inhalants on the body Define inhalant intoxication, withdrawal, tolerance and addiction Identify emergency treatment Recognize fatal and long-term consequences of inhaling Correlate the relationship of inhalant abuse and delinquent behavior List three clinical/nursing interventions to assist the patient who abuses inhalants Complete exam components at a 70% competency Introduction Inhalant abuse is a growing trend and it can be challenging to recognize the early warning signs, which makes it more difficult to treat. Recognizing the signs and symptoms of inhalant abuse is an important assessment tool of any health care provider. As an important aspect of health promotion in the pediatric and adolescent population, screening efforts should address conditions that cause significant morbidity and mortality before it becomes life threatening. According to the American Family Physician (AFP) about one-quarter of school aged children 'huff'. In addition, the AFP revealed that the average age of children is 12 years of age when they first see or hear about a classmate who huffs. There are an alarming number of youths inhaling chemicals for euphoric purposes. Previously considered a drug of adolescents, inhalants are being used increasingly by preteen aged children, some as young as 5 and 6years old. Cheap and abundant, inhalants are an easy way for youths to "get high". These substances are physically and psychologically addicting and can cause death. Nurses need to be able to recognize the signs of inhalant abuse. This is especially important, because most abusers seek help for medical or psychological problems, without mentioning the source of the problemsInhalants. Bottom of Form Top of Form Bottom of Form Statistics Inhalants have been used throughout history to alter consciousness. Statistics from 2008 show a decline in the use of inhalants by youths. In the past decade there has been a concerted effort to educate healthcare professionals, educators, law enforcement, retailers, youths and parents about inhalants. Although there is a decline in overall usage, inhalants are being used by a significant number of school children. For example, more than 15% of eighth graders have used inhalants. Another statistical "red flag" is that there is a decline in the number of youths who do not perceive using inhalants are detrimental. Monitoring the Future (MTF) is an ongoing study for the National Institute of Drug Abuse (NIDA) of the behaviors, attitudes, and values of American secondary school students, college students, and young adults. The following is from the 2008 data: Drug usage--Each year, a total of 50,000 8th, 10th and 12th grade students are surveyed. The 2008 MTF marks the sixth year in a row that illicit drug use among 8th, 10th, and 12th graders remained stable or decreased. In particular, the proportion of 8th and 10th graders reporting the use of any illicit drug in the prior 12 months declined significantly from 2007 to 2008. The decrease in illicit drug use among 8th graders continues a decline begun in 1997, but this is the first significant decline among 10th graders since 1998. Inhalant usage--In 2008, inhalant use among 8th and 10th graders was the lowest seen in these grades since their addition to the survey in 2001. Among 8th graders, lifetime* use decreased from 17.1% in 2007 to 15.2% in 2008, and from 15.2% to 13.5% among 10th graders. Use rates among 12th graders were at their lowest in about 20 years. Perceived risk of inhalants--However, the 2002 survey reported a decline among 8th graders in the perceived risk of trying inhalants once or twice, and the perceived risk of regular use of inhalants also decreased among 10th graders. Historically, changes in "perceived risk" tends to predict increases or declines in use rates for following years. *"lifetime" refers to using the drug at least once during a respondents lifetime. Prevalence of Inhalant Abuse Most children and adolescents say they are aware of people who breathe in fumes of household products such as glue, paint, or cleaners, and nearly 25% say their friends 'huff' according to the American Academy of Pediatrics who sponsored a survey on inhalant abuse. The survey found that 62% of the 10 to 17 year-olds surveyed know what huffing is. Only 67% of children 10 to 11 years of age have learned about inhalants in the classroom, and only 48% have talked with their parents about inhalant abuse. But, this age group is the most likely to have been personally exposed to inhalants. The abuse of inhalants is widespread across the United States; however, it may be underreported because law enforcement officials and healthcare providers are often unfamiliar with the signs of inhalant abuse. Almost 17 million individuals have experimented with inhalants at some point in their lives. Inhalants are the 4th most abused substances in the United States among 8th, 10th, and 12th graders; alcohol, cigarettes, and marijuana are the top three according. Bottom of Form Top of Form Bottom of Form Facts About Inhalant Abuse Users inhale vapors from a wide range of substances found in more than 1,000 common household products. Inhalants are breathed in through the nose or mouth in a variety of ways. Abusers begin by inhaling deeply; they then take several more breaths. Abusers may inhale, by sniffing or snorting, chemical vapors directly from open containers or by huffing fumes from rags that are soaked in a chemical substance and then held to the face or stuffed in the mouth. Other methods include spraying aerosols directly into the nose or mouth or pouring inhalants onto the users collar, sleeves, or cuffs and sniffing them over a period of time, such as during class. In a practice known as bagging, fumes are inhaled from substances sprayed or deposited inside a paper or plastic bag. Alternatively, the fumes may be discharged into small containers such as soda cans and then inhaled from the can. Users may also inhale from balloons filled with nitrous oxide or other devices such as snappers and poppers in which inhalants are sold. Inhalants are substances whose vapors can be inhaled to produce a mind-altering effect and can be categorized as: Volatile solvents are liquids that vaporize at room temperature when left in unsealed containers. They are found in gasoline, felt-tip markers, paint thinners, correction fluids, some nail polish removers, degreasers, and glues. Aerosols are spray containers containing propellants and solvents such as toluene. Common aerosols include hair spray, vegetable oil sprays used in cooking, whipping cream, paint, deodorant and fabric protector. Silver and gold paint are especially popular among inhalant abusers. Gases are substances with no definite shape or volume. Abusers inhale gases found in butane lighters, air conditioning units, ether, nitrous oxide, and propane tanks. The most commonly abused gas, nitrous oxide, is found in whipped cream dispensers and products that boost octane levels in racing cars. It is also sold at raves or drug paraphernalia stores in the form of balloons or as vials called "whippets" Nitrites such as cyclohexyl nitrite, amyl nitrite, and butyl nitrite are used mainly to enhance sexual experiences. They are available in adult bookstores and over the internet. Cyclohexyl nitrite is also found in room deodorizers. Abusers use several different techniques to inhale: "Huffing" involves inhaling vapors from a cloth soaked in a volatile substance, which is then held over the mouth and nose. Huffing is preferred by 60% of youths; "Sniffing" implies inhaling vapors from an open container. Sometimes a substance such as glue is heated in a frying pan. Other times a small confined area, such as a closet or automobile, is filled with vapors such as butane; "Spraying" implies spraying an aerosol directly into the mouth; "Bagging" refers to placing the volatile substance into a plastic bag which is then held over the mouth and nose. The above products are usually a mix of toxic and poisonous chemicals. Many have a strong smell and inhalants are not illegal drugs like cocaine or crack. Instead, they are used for specific purposes like cleaning, making model airplanes, or fueling cars. If used correctly, inhalants are generally safe for their intended purpose. Like illegal drugs, inhalants are dangerous for people to take into their bodies. Youths are divided between those who experiment with inhalants (50%) and those who were heavy users (50%). Street Terms for InhalantsAmysBangBoltBoppersBulletClimaxGladingGlueyHardwareHead cleanerHippie crackKickLocker roomPoor man's potPoppersRushSnappersToncho (octane booster) What are the Effects? Inhalants act like a poison once inside the body. When someone sniffs or huffs, the toxic gases rush into the lungs, where it is rapidly transported to the pulmonary alveoli. The alveoli have a large capillary network that promotes the absorption of inhaled substances into the blood. Then the gases speed into the bloodstream to carry the poisons into the muscles and organs such as the brain, heart, kidneys, and liver. Once the inhalant binds with hemoglobin, (a compound in the blood that carries oxygen), it will prevent the blood cells from picking up oxygen in the lungs. As a result, the oxygen cannot reach the brain and suffocates the person who huffs the toxic chemical. Due to their easy absorption into fat, solvents are readily transported to the brain. They have direct effects on both the central nervous system (brain and spinal cord) and the peripheral nervous system (nerves throughout the body). Some of the inhalants leave through the lungs, kidneys, and skin. You can actually smell an inhalant odor on an abusers skin or breath. Most of the inhalantbut not necessarily all of itleaves the body within two weeks. Some of the toxic chemicals are stored in the bodys fat forever. They remain in the fatty tissue of the brain, nervous system, kidneys, liver, heart, and muscles and can cause permanent damage. Death from inhalant abuse can occur after a single use or after prolonged use. The most serious hazard for inhalant abusers is a syndrome called 'sudden sniffing death', which may result within minutes of inhalant abuse from irregular heart rhythm leading to heart failure and death. Other causes of death include asphyxiation, aspiration, or suffocation. A user who is suffering from impaired judgment may also experience fatal injuries from motor vehicle accidents or sudden falls. Chronic exposure to inhalants causes widespread and long-lasting damage to the nervous system and other vital organs. The toxic chemicals damage parts of the brain that control learning, movement, vision, and hearing. Damage to the heart, lungs, liver, and kidneys may be permanent. Top of Form Bottom of Form Top of Form Bottom of Form Inhalant intoxication can develop within 5 minutes and generally subsides in approximately one hour. The inhalant abuser that has recently been inhaling typically presents with a disheveled appearance, chemical odor on the breath and clothes, and stains on skin and clothes. Why are Inhalants Used? Healthcare professionals, teachers and parents have difficulty understanding the appeal of inhalants to youths. The following are some of the reasons they have been found to be appealing: A rapid onset of effect--A "high" is reached within a few minutes of inhaling, much quicker than an alcohol induced high. Youths often want instant gratification and inhalants provide this; Quality and pattern of the high--Abusers describe effects such as euphoria, giddiness, and lightheadedness. Some users experience a surge of creativity; others describe feelings of excitement; Low cost--Many who abuse inhalants have limited incomes or are children who do not have the financial means to purchase other drugs. Poverty and lack of opportunity potentiate inhalant use; Easy to conceal--Youths frequently carry the product they abuse with them, often for use in the classroom or at social functions. Parents unfamiliarity with the abuse potential of inhalants contributes to their attractiveness for youngsters. They are easy to conceal from parents, there are no dealers, no paraphernalia, no needles or track marks; just a small container of frequently used products such as nail polish; Legality--Purchase and possession of these substances is not restricted or illegal in most areas. Some states have laws that prohibit the inhalation of these products in public places; Easily available--Inhalants are different from other drugs in that they are not sold illegally on street corners, parking lots and malls. Inhalants can also be purchased in numerous retail stores and sometimes are shoplifted or used in retail stores, without purchasing. Inhalants are in many rooms in our homes. Some nitrite abusers (who tend to be adults rather than adolescents) seek to enhance the sexual experience. Inhaled nitrites dilate blood vessels, increase the pulse rate, and produce a sensation of heat and excitement that can last several minutes. Bottom of Form Top of Form Bottom of Form Characteristics of Users Parents frequently deny the possibility that their child has used inhalants. Children without support systems and positive coping mechanisms frequently look to inhalants as a method of escaping their problems. Such youths may have the following characteristics: Emotional stress - Sometimes a crisis has recently occurred either at school or at home; Dysfunctional Home - Frequently one or both parents use alcohol or drugs; Risk taker - Youths are frequently risk takers and use inhalants even though they have heard of the detrimental effects. Typically, they do not believe the effects will apply to them; Low self esteem - These individuals have a low opinion of themselves and are often vulnerable to peer pressure. Bottom of Form Top of Form Bottom of Form Gender and Inhalant Use A decade ago, inhalants were considered a drug abused by males. According to studies, these demographics have changed: There are no gender differences in age of onset of inhalant use, lifetime frequency of inhalant use, frequency of inhalant use in the past, or preferred method of using inhalants; There is a continued increase of inhalant use among females compared to males. Ethnicity Literature from the 80s described the typical user of inhalants as a Native American or Hispanic male. New data has found that there is a strong pattern of decreases in inhalant use among Native American adolescents over the last decade. Data indicates that a number of social and perceptual correlates of inhalant use operate similarly across Mexican American, Native American and non-Latino white adolescents. Peer factors appear dominant, although they are somewhat less important for Mexican American and Native American youths. Increased perception of harm has reduced inhalant use for all groups. Reporting of inhalant usage is also affected by ethnic background. White youths (36.1%) and youths from other ethnic backgrounds (44.4%) are significantly more likely to report past inhalant use than African-American youths (1.4%). Bottom of Form Top of Form Bottom of Form Where Do Inhalers Use? Research shows that 60% of youths reported using inhalants with friends present, whereas 40% used inhalants when they were alone. Sites where youths reported inhalant use include: at a friends home (68%), at their own home (54%), on the street (40%), at parties (28%), on school grounds (26%) at school (18%) Researchers categorize people who abuse substances on the basis of length of abuse and whether they use such substances alone or in the presence of others. Transient abusers have a short-term history of abuse: Transient social abusers tend to be preteens or teenagers who use substances in the presence of others. Legal problems include minor offenses while intoxicated; Transient isolate abusers are in the same age group but tend to abuse solvents while alone. This group is unlikely to have legal problems. Chronic abusers have used for years: Chronic social abusers tend to be in their 20s and 30s and have used substances in the presence of other for years. Legal problems include misdemeanors; Chronic isolate abusers are in the same age group, but abuse drugs while alone. Legal problems include significant offenses including assaults. Chronic abusers of inhalants often starting using inhalants early in life, but instead of moving on to other drugs, choose a certain inhalant as their drug of choice. For example, they may choose to use only gold spray paint. Bottom of Form Signs of Use Signs of inhalant abuse can include: Unusual breath odor or chemical odor on clothing Sitting with a pen or marker near the nose Slurred or disoriented speech Anxiety, excitability, irritability or restlessness Drunk, dazed or dizzy appearance Constantly smelling clothing sleeves Showing paint or stain marks on the face, fingers or clothing Hiding rags, clothes or empty containers (such as air fresheners) of the potentially abused products in closets and other places Signs of paint or other products where they wouldnt normally be, such as on the face or fingers Red or runny eyes or nose Spots or sores around the mouth Nausea or loss of appetite Lack of coordination Nausea or loss of appetite Failing grades, chronic absence and general apathy Bottom of Form Withdrawal - Tolerance - Addiction According to the APA, a withdrawal syndrome has been described that can begin 24-48 hours after cessation of use and last from 2 to 5 days. Symptoms include sleep disturbances, tremor, irritability, diaphoresis, nausea and fleeting illusions. Youths often complain of headaches or abdominal cramps. Parents and healthcare personnel often think these symptoms are simply symptoms of "the flu." Additional symptoms exhibited by long-term inhalant abusers include weight loss, muscle weakness, disorientation, inattentiveness, irritability, and depression. Withdrawal symptoms include: Sweating Rapid pulse Hand tremors Insomnia Nausea Vomiting Grand mal seizures Liver disease (hepatitis or cirrhosis) Acute or chronic renal failure Sleep disturbances Bone marrow depression Cardiac arrhythmias Respiratory damage (lung or sinus damage, pneumonitis, emphysema, ling changes or respiratory depression) If users inhale these substances continually and increase the amounts, they will develop a tolerance. This means that they will have to use the inhalants more frequently and in greater volume to get the desired effect. Recurrent inhalant use may result in the individual giving up or reducing important social, occupational or recreational activities. Also, substance use may continue despite the individuals knowledge of physical problems (e.g., liver disease, central and peripheral nervous system damage) or psychological problems (e.g., severe depression). The potential for addiction as well as psychological dependence is high. Assessment Careful assessment of persons who are potentially using inhalants is vital in helping individuals avoid the serious complications. Due to the variety of health problems associated with inhalant use, and the vagueness of many of the symptoms of use, a thorough assessment is necessary. Clients can be encountered in a number of health care settings, including schools, clinics, psychiatric or addictions counseling environments, emergency rooms and throughout the acute care settings. Sometimes inhalers are referred for healthcare assessment by the legal system or social service agencies. The assessment process should include a  HYPERLINK "http://www.rnceus.com/inhal/hist.htm"history,  HYPERLINK "http://www.rnceus.com/inhal/phys.htm"physical,  HYPERLINK "http://www.rnceus.com/inhal/psych.htm"psychological and  HYPERLINK "http://www.rnceus.com/inhal/diag.htm"diagnostic evaluation. History The quality and quantity of data elicited will depend on the practitioners sensitivity to the client. The practitioners communication style is adapted to specific circumstances. If the client is intoxicated, the interview may have to be conducted after detoxification. Completing a history may be difficult and frequently must be carried out over a period of time. This is necessary to distinguish between manifestations that are due to intoxication versus long-term complications. Information must be collected on the inhalant abused; the manner, duration, and frequency of abuse, and the use of other chemicalssuch as alcoholin addition to the inhalant. Sample questions include: At what age did you start inhaling? When did you last inhale? Have you ever passed out from inhaling? Have you experienced hallucinations? Do you notice a decrease in your ability to concentrate? Is it difficult to stop huffing once you have started? In addition to obtaining a medical history that asks questions pertaining to the effects of inhalants, it is recommended that the person who is performing the assessment obtain information pertaining to childhood disease, history of injuries and acute or chronic infections (including STDs). Clients under the influence of chemicals often do not take precautions to protect themselves from sexually transmitted disease. Additionally, the client should be requested to sign a release of medical information. Depending on the age of the client, some of the data may need to be obtained from a parent /guardian. The following collaborative information is helpful: Change in behavior or attendance at school; teachers will frequently report a change in grades or conduct in the classroom Arrest for substance abuse offense. Youths frequently display deviant, disruptive or delinquent behavior Personality changes Physical Assessment Manifestations vary, depending on the types of inhalants, amount of substances used and the duration of the use. The physical assessment should include objective and subjective data. The following systems should be assessed. Objective data should be collected with consideration for the possibility of the following disorders: Cardiovascular - After a solvent is inhaled, a peripheral vasodilatation results, with variable degrees of hypotension and reflex tachycardia. Chronic exposure to volatile substances may cause dilated cardiomyopathy or myocarditis and additionally cases of cardiac arrhythmias and myocardial infarction; Neurologic - Cerebral cortex damage can cause changes in personality, memory loss, hallucinations and learning problems. Cerebellum damage can cause problems in balance and movement. Hippocampus damage may result in memory problems. Peripheral neuropathy has been reported secondary to chronic inhalant abuse; Respiratory - Coryza, pharyngitis, and pulmonary failure from aspiration are consequences of inhaling. Rales, rhonchi, bronchitis and pneumonia may be noted. The diagnosis of Inhalant abuse is often missed, and the respiratory condition may be treated without an evaluation of the cause; Gastrointestinal - Nausea, vomiting, and abdominal pain may be noted during intoxication and withdrawal. Manifestations of chronic abuse include anorexia and weight loss. Impaired liver function may be noted; Musculoskeletal - Muscle weakness has been noted from using products that contain toluene, such as lacquer thinner; Urological - The renal tubules may suffer damage from inhalants, altering electrolyte levels; Hematology - Bone marrow depression is a complication of inhalant abuse. Toxic effects of inhalant abuse include anemia, thrombocytopenia, leukemia, and hemolysis; HEENT - Often the inhalant is placed in a plastic bag and the fumes are inhaled by mouth ( HYPERLINK "http://www.rnceus.com/inhal/inmethod.htm" \l "huff"huffing). This causes sores in the mouth or a rash around the mouth.  HYPERLINK "http://www.rnceus.com/inhal/inmethod.htm" \l "sniff"Sniffing causes chronic nosebleeds and sores in the nose. Freezing of the lips and mouth can occur when the substance is inhaled directly from a cylinder. Other manifestations include tinnitus, sneezing, hyper salivation and conjunctival irritation. Bottom of Form Top of Form Bottom of Form Psychological Assessment The inhalant abuser may appear apathetic or belligerent and exhibit impaired judgment. Family and school officials often dismiss these manifestations as just adolescent behavior. Other behaviors to observe for include: Difficulty concentrating Irritability Depression Apathy Hostility Violent temper outbursts Paranoia Hallucinations Anxiety Lack of motivation Mood swings Specific questions should be asked in the following areas: Previous suicidal ideation/plan Actual suicide attempts in past (dates and methods) Current suicidal ideations/plan Previous psychiatric care/current psychiatric care Symptoms of depression Recent loss of significant others, including pets Feelings of hopelessness/helplessness Sleep and appetite disturbances Social withdrawal Bottom of Form Top of Form Bottom of Form Diagnostic Evaluation Inhalant users should be assessed with computed tomography (CT) and magnetic resonance imaging (MRI) studies of the brain. Most inhalants contain solvents which target and dissolve fatty tissue in the brain, liver, kidneys and adrenal glands. New research suggests inhalants also dissolve the myelin sheath of neurons in the brain; Inhalants are not detected by routine drug screens, but a routine drug screen is recommended to rule out other drugs. Laboratory identification of inhalant abuse most often requires analysis of body fluids by gas chromatography; A complete blood count (CBC) should be performed to determine if any of the following are present: infection, anemia, leukocytosis, thrombocytopenia, thrombocytosis, or platelet defects; Creatinine, blood urea nitrogen (BUN) and urinalysis to assess kidney function should be included in the workup; Serum electrolytes should be assessed to determine if there is an electrolyte imbalance such as hypercholeremia, hypokalemia and hypophosphatemia; Electrocardiogram (ECG) and chest x-ray should be used to determine heart and lung damage; Visual and auditory-evoked potentials are abnormal in children who have significant abuse history; Neuropsychologic testing is recommended. Bottom of Form Top of Form Bottom of Form Fatal Consequences of Inhalant Use Death from using inhalants can occur from several factors: Injury - Impaired judgment is a consequence of inhalant abuse. Inhalers have been known to try and swim across a river or fly off a building; Asphyxiation and Suffocation - Asphyxiation is caused from repeated inhalations, which lead to high concentrations of inhaled fumes displacing the available oxygen in the lungs. Suffocation occurs from blocking air from entering the lungs when inhaling fumes from a plastic bag placed over the head; Choking - Users can choke on their own vomit; Suicide - A frequently used method of inhalation is for the abuser to place a plastic bag over the head or wrap the body in plastic with the inhalant enclosed. As a result, the inhaler passes out from the inhalant and suffocates to death; Sudden death - Sudden death is caused from a cardiac arrhythmia. According to Harvey Weiss, director of the National Inhalant Prevention Coalition, "Inhalants can cause serious central nervous system damage and death. They sensitize the heart to adrenaline, so a sudden rush of adrenaline, combined with inhalant use, can make the heart stop instantly. This phenomenon is known as sudden sniffing death syndrome and can occur the 1st, 10th, or 100th time someone uses an inhalant." Sudden sniffing death, as it is called, is responsible for more than half of all deaths due to inhalant abuse. Bottom of Form Top of Form Bottom of Form Long Term Consequences Kaposis Sarcoma - Amyl and butyl nitrates have been associated with Kaposis sarcoma, the most common cancer reported with AIDS patients. Early studies of Kaposis sarcoma showed that many people with Kaposis sarcoma had used volatile nitrates. Researchers are continuing to explore the hypothesis that nitrates are a contributing factor to the development of Kaposis sarcoma in HIV-infected people; Inhalant Induced Persisting Dementia - In order for this type of dementia to be diagnosed, there must be evidence from the history, physical exam or laboratory findings that the deficits are etiologically related to the persisting effects of inhalants. This disorder is termed "persisting" because the dementia persists long after the individual has experienced the effects of inhalant intoxication and withdrawal; Burns - The highly flammable nature of inhalants leads to burns. Inhalants cause impaired judgment. Youths have received burns from lighting a cigarette while inhaling, or, in rural settings, throwing a used inhalant container in a bonfire; Developmental harm to fetuses - Abuse of inhalants during pregnancy may place infants and children at increased risk of developmental harm. Further, in these children report some evidence of retardation in growth and development and residual deficits in cognitive, speech, and motor skills; There is also some limited evidence of neonatal withdrawal from inhalants. It is recommended that infants born to women who have recently used inhalants be observed carefully for an alcohol-like withdrawal syndrome; Although it is not possible to link a specific birth defect or developmental problem in the child of an inhalant abuser to prenatal exposure to a specific chemical, it is clear that inhalant abuse places children at increased risk. Animal studies, designed to simulate human patterns of inhalant abuse, suggest that prenatal exposure to toluene or trichlorethylene (TCE) can result in reduced birth weights, occasional skeletal abnormalities, and delayed neurobehavioral development; A number of case reports note abnormalities in newborns of mothers who chronically abuse solvents. There is also evidence of subsequent developmental impairment in some of these children. However, no well-controlled, prospective study of the effects of prenatal exposure to inhalants in humans has been conducted, and it is not possible to link prenatal exposure to a specific chemical to a specific birth defect or developmental problem. Bottom of Form Top of Form Bottom of Form Delinquent Behavior & Inhalant Use More minor criminal activity has been reported among inhalant users and experimenters in upper (9-12) grade level students, than other drug users and experimenters of the same age. There is a similar trend for "trouble behavior." Again, the same was not found for drinking and drug-taking behavior. The findings suggest that inhalant use is categorically different from other drug use, and that it has more in common with general delinquency than with general drug use. Addiction Treatment Effectiveness Treatment facilities for inhalant abusers are hard to find. Program directors of drug user treatment programs have been surveyed, and the research shows that they perceive a great deal of neurological damage incurred through inhalant use. They also have a general pessimism about treatment effectiveness and recovery. Detoxification averages 40 days and treatment for inhalant abusers is usually long-term, sometimes as long as 2 years. It must address the many social problems most inhalant abusers have and involves: Support of the child's family Moving the child away from unhealthy friendships with other abusers Teaching and fostering better coping skills Building self-esteem and self-confidence Helping the child adjust to school or another learning setting Relapse Patterns leading to addiction are hard to erase, and recovering from inhalation abuse involves more than simply abstinence. Inhalant abusers have high relapse rates, making aftercare and follow-up extremely important. During treatment, many of the stresses of everyday life are removed. Returning to the previous life may produce all of the old problems. The warning signs of relapse include returning to old habits, friends, hangouts or denial. An example of denial is "I no longer have to worry about using inhalants." Without on-going support, the persons coping mechanisms may be too fragile to resist returning to old patterns. The following are recommended: Aftercare - Aftercare takes a variety of forms. It often includes a structured plan for relapse prevention and active participation in treatment issues. For many users, treatment must continue for an extended period of timepossibly up to two years. Support Group - Groups such as NA or AA use a 12-step approach to help the recovering person develop a different life style. Hearing the facts from those who are recovering and are willingly making the commitment to achieve a drug-free lifestyle is a particularly effective part of the persons support. Sponsor - Each newly recovering person will benefit from having a sponsor. A sponsor is a recovering person who is always available to the new member by telephone for encouragement, for clarification, and as a sounding board, particularly during the early stages of recovery. Youths need empathetic health care professionals who are committed to helping them receive appropriate treatment. They also need acceptance and understanding as they begin their recovery. General Clinical/Nursing Interventions During the acute phase of inhalation intoxication and detoxification, care focuses on maintaining the patient's vital functions, ensuring his/her safety, and easing discomfort. During the rehabilitation, caregivers help the patient acknowledge his/her substance abuse problem and find alternative ways to cope with stress. Health care professionals can play an important role in helping patients achieve recovery and stay drug-free. The following are clinical/nursing interventions that are appropriate for patients during and after acute intoxication: During an Acute Episode: Continuously monitor the patient's vital signs and urine output Maintain a quiet safe environment. Remove harmful objects from the room. Institute appropriate measures to prevent suicide attempts and assaults, according to facility policy Approach the patient in a nonthreatening way. Limit sustained eye contact which s)he may perceive as threatening Implement seizure precautions Give medications, as ordered, monitoring and recording their effectiveness. Medications may include Haldol (for severe agitation), sedatives (to induce sleep), anticholinergic and antidiarrheal agents (to relieve GI distress), antianxiety Rx. During Drug Withdrawal: Administer medications, as ordered, to decrease withdrawal symptoms, monitoring and recording their effectives Maintain a quiet, safe environment because excessive noise may agitate the patient. When the Acute Episode Has Resolved: Carefully monitor and promote adequate nutrition Administer drugs carefully to prevent hoarding. Check the patient's mouth to ensure that (s) he has swallowed oral medication. Closely monitor visitors who might supply him/her with drugs Refer the patient for rehabilitation as appropriate. Give him/her a list of available resources Encourage family members to seek help regardless of whether the abuser seeks it. Suggest private therapy or community mental health clinics Develop self-awareness and an understanding and positive attitude toward the patient. The health care professional should control their reactions to the patient's undesirable behaviors---commonly, psychological dependency, manipulation, anger, frustration and alienation Set limits when dealing with demanding, manipulative behavior Bottom of Form Top of Form Bottom of Form Prevention is the Key Prevention of inhalant abuse is the goal. This involves the entire community, including healthcare professionals, teachers, parents, peers, law enforcement and retailers. This section provides information for nurses to assist in the education of others. Teaching children about inhalants Children need to be able to differentiate between "good smells" (i.e., cookies baking). and "bad smells" (i.e., gas). Children who have used inhalants have said, "I had no idea that breathing in these products could hurt me." It is recommended to start anticipatory guidance early. Six year-old children are not too young to be taught the dangers of inhalants. Talking to parents about inhalants Parents frequently deny that inhalants could be a problem in their families, schools or communities. More than nine out of ten parents refuse to believe their children may have ever abused inhalants. While 91% of parents said they had talked to their children about substance abuse, less than half of those parents had specifically mentioned inhalants. Rural communities may deny the existence or extent of addiction, so awareness of inhalant use is often minimal. Some states have laws to try and deal with inhalant abuse, but such laws are not always easy to enforce. Since inhalants are legal and kids can obtain them in so many different ways, it is not possible to make inhalants entirely off-limits. The American Academy of Pediatrics recommends that the best way to fight inhalant abuse is to educate children about how harmful these products are. They advocate explaining how they can cause short- and long-term health problems, further drug abuse, and death. Parents and teachers should also be able to recognize the warning signs of inhalant abuse. Some suggestions are: Do not shut children out by simply saying something is 'bad for you'. Educate yourself and then give your child the right information. Talk about dangerous behavior, such as inhalant abuse, and explain the consequences. Help your child develop refusal skillshow to say 'no'. Listen to your child. Talk with them to learn what pressures they are exposed to and what they are thinking and feeling. Ask your child questions such as 'where are you going?' or 'who will you be with?' If you think your child is into inhalant abuse, remain calm. Upsetting them may make them more violent or trigger a physical response such as sudden sniffing death. If the latter occurs, ensure a well-ventilated room and seek medical attention quickly. Conclusion Inhalant abuse is growing, is a frightening problem and can be challenging to recognize early. Easy accessibility and the relatively low cost of the substances abused indicate that inhalant abuse will attract new users and continue to be a problem. Although it is often a transient phase of drug experimentation, inhaling may lead to addiction or other drug usage. The statistics of inhalants usage are decreasing across America, but this is not a time to become complacent. First time usage can result in death or in permanent disability. Inhalants are dangerous poisons that were never designed for human consumption. The most effective way to prevent inhalant abuse is by educating providers, healthcare workers, teachers, and parents. Information can only increase awareness of the negative effects of inhalant abuse and may help to make this practice less appealing to our nations youth. Parents may not realize that they have only a few short years in which they can influence their childs decision not to abuse inhalants. It is important that nurses have full access to information that would help them identify inhalant abuse. The risks add up. Why do abusers take such a risk? Usually because the either are not aware of the risk or they do not think it applies to them. What the abuser fails to realize is that they are not getting 'high' but they are feeling the lack of oxygen in their brain. Nurses need to take the leadership in assessing youth, in educating other health care professionals, educators and the public. Inhalant abuse must not remain an invisible problem. Nurses need to play an integral role in identification, prevention and education. Classes and Examples of Inhalants There are approximately 1400 available products that youths inhale to get high. These inhalants fall into four categories: Volatile solvents - These are found in various fuels and paints.  The glue sniffers of the 1960s popularized this class of inhalants. Products abused in this category include gas, "goop" (a product to resole shoes), lighter fluid, paint, kerosene, gun cleaning solvent, cleaning fluids, nail polish, nail polish remover, rubber cement, paint thinner, varnish, spot remover, toxic markers, and propane. Aerosols - These products are readily available in virtually every household. Products abused in this category include hair spray, spray paints, spray deodorants, frying pan lubricants, air fresheners, freon, computer "dust-off", and fabric protectors. Asthma inhalers are also abused. Like other aerosols, they contain fluorocarbons, which produce euphoric effects. Peers refer to individuals who choose this product as "spray heads." Nitrates - Inhalant nitrates including amyl nitrate (street names "poppers" and "snappers"), which was originally prescribed for heart patients. Butyl nitrate (street names "rush", "bolt", "locker room", "bullet" and "climax") is sold as room freshener. Nitrates are also sold as aphrodisiacs in adult bookstores and through mail order catalogs. Anesthetics - Products abused in this category include ether, chloroform and nitrous oxide. Nitrous oxide is commonly called "laughing gas" and used by dentists. Nitrous oxide is also sold in balloons at rock concerts and available in small cylinders known as "whippets." The five substances most frequently used as inhalants include gasoline (by 57.4%), freon (40.45%), butane lighter fluid (38.3%), glue (29.8%), and nitrous oxide (23.4%) Diagnostic criteria for 292.89--Inhalant Intoxication The following is the American Psychiatric Association (APA) DSM-IV-TR (2000) criteria for inhalant Intoxication: A. Recent intentional exposure to short-term, high dose volatile inhalants (excluding anesthetic gases and short-acting vasodilators); B. Clinically significant maladaptive behavioral or psychological changes (for example, belligerence, assaultiveness, apathy, impaired judgment, impaired social or occupational functioning) that developed during, or shortly after, use of or exposure to volatile inhalant; C. Two (or more) of the following signs, developing during, or shortly after, inhalant use or exposure: 1. Dizziness 2. Nystagmus 3. Incoordination 4. Slurred speech 5. Unsteady Gait 6. Lethargy 7. Depressed reflexes 8. Psychomotor retardation 9. Tremor 10. Generalized muscle weakness 11. Blurred vision or Diplopia 12. Stupor or Coma 13. Euphoria D. The symptoms are not due to a general medical condition and are not better accounted for by another mental disorder. According to the APA, during intoxication, acute central nervous system manifestations include euphoria accompanied with feelings of grandiosity and increased awareness, understanding and insight. Inhalers experience a distortion of space and visual perception. Common statements include "the walls are closing in" or the "the sky is falling." Some youths use inhalants specifically for their hallucinogenic effect. A popular practice is for groups of users to inhale together and then compare their hallucination. They describe such sensations as "seeing vivid colors" or "hearing sirens." Other DSM-IV Inhalant Related Disorders 304.60 Inhalant Dependence 305.90 Inhalant Abuse 292.81 Inhalant Intoxication Delirium 292.82 Inhalant Induced Persisting Dementia 292.9 Inhalant-Related Disorder NOS Emergency Treatment Medical Airway management-- Prevention of aspiration is essential. High-flow oxygen via a mask or by endotracheal tube is recommended, if indicated; Vital signs and cardiac monitoring; IV for hydration and access for administration of emergency drugs; Calm environment--Inhalants cause an increased release of catecholamines leading to increased heart rate and blood pressure. If the client becomes frightened, it can lead to additional release of catecholamines; In the event of accidental ingestion of an inhalant, it is recommended that a nasogastric tube be placed and aspirate the stomach contents within one hour of ingestion. The contents will absorb into the bloodstream after one hour. Neither syrup of ipecac, activated charcoal or aggressive gastric lavage is recommended. Ipecac could cause aspiration of the solvent secondary to vomiting. Activated charcoal doesnt absorb solvents well and if vomiting from activated charcoal occurs, the aspiration risk increases. Medication--There is no recommended medication for withdrawal of inhalant abuse. However, individual symptoms can be treated with medication for manifestations of inhalant abuse. Mental Health Psychological and addiction evaluation--. The abuser may be anxious to convince healthcare personnel that they will never abuse inhalants again; denial is a common symptom of addiction. However, youths should be referred for an addiction and psychological evaluation. A psychological evaluation is necessary to rule out concurrent mental health problems. What to Do When Someone is Huffing Remain calm and do not panic. Do not excite or argue with the abuser when they are under the influence, as they can become aggressive or violent. If the person is unconscious or not breathing, call for help. CPR should be administered until help arrives. If the person is conscious, keep him or her calm and in a well- ventilated room. Excitement or stimulation can cause hallucinations or violence. Activity or stress may cause heart problems which may lead to "Sudden Sniffing Death." Talk with other persons present or check the area for clues to what was used. Once the person is recovered, seek professional help for abuser: school nurse, counselor, physician, other health care worker. If use is suspected, adults should be frank References American Academy of Pediatrics: 2002, Preventing Inhalant Abuse, American Psychiatric Association: 2000, Diagnostic and statistical manual of mental disorders (4th ed. text revision), Washington D.C. Beauvais, Jumper-Thurman, Plested, & Helm: 2002, A survey of attitudes among drug user treatment providers toward the treatment of inhalant users, Substance Use & Misuse, 37 (11), 1391-410 Beauvais, Wayman, Jumper-Thurman, Plested, & Helm: 2002, Inhalant abuse among American Indian, Mexican American, and non-Latino white adolescents, American Journal of Alcohol Abuse, 28 (1), 171-87 Bykowski, M.:1999, Dont miss inhalant abuse diagnosis, Pediatric News, 33 (10), 37 Cobaugh, D.:1999, Inhalant abuse, Journal of Emergency Services, 24 (10), 66-75 Cook, K.:1999, Assessment of potential inhalant use by students, Journal of School Nursing, 15 (5), 20-23 Espeland, K.:2000, Inhalant abuse, Lippincotts Primary Care Practice, 4 (3), 336-340 Howard M. & Jenson J.:1999, Inhalant use among antisocial youth: Prevalence and correlates, Addictive Behaviors, 24 (1), 59-74 Ives R.:1997, Volatile substance misuse, Journal of Substance Misuse, 2, 54-56 Jones, H. & Balster, R.:1998, Inhalant abuse in pregnancy, Obstetrics and Gynecology Clinics of North America, 25 (1), 153-67 Lien-Munson, B.: 2002, How to recognize and treat propellant inhalation, Dimensions of Critical Care Nursing, Jan/Feb 2002, Vol 21 issue 1, p18 LoVecchio, F. & Gerkin, R.:1997, Inhalants of abuse, Topics in Emergency Medicine, 19 (4), 44-52 McPhee, A. T.:1999, High risk, Current Science, 10/8/99, Vol 85 issue 3, p10 McGarvey E., Clavet G., Mason, W., & Waite, D.:1999, Adolescent inhalant abuse: environments of use, American Journal of Drug Alcohol Abuse, 25 (4), 731-41 Mackesy-Amiti M. & Fendrich M.:1999, Inhalant use and delinquent behavior among adolescents: a comparison of inhalant users and other drug users, Addiction, 94 (4), 555-64 Munson: 2002, How to recognize and treat propellant inhalation, Dimensions of Critical Care Nursing, 21 (1), 18-19 National Clearinghouse for Alcohol and Drug Information of the United States Public Health Service: 2008 National Drug Intelligence Center, Department of Justice, 2001, Intelligence brief: huffing National Inhalation Prevention Coalition: 2003, National Institute of Drug Abuse: Mind over Matter, National Institute of Drug Abuse: 2008, National Institute of Drug Abuse, National Youth Anti-Drug media Campaign: 2008, National Medical Society: 2008, New Straits Times-Management Times, 20008, deadly sniff Palmer, R.:1997, Huffers and sprayheads: managing the volatile-substance abuse patient, Emergency, 29 (6), 40-42 Preboth, Monica: 2000, Prevalence of inhalant abuse in children, American Family Physician, 02/15/2000, Vol 61 issue 4, p1206 Ravetti, L.:2000, Patient education for the recovering individual, Lippincotts Primary Care Practice, 4 (3), 341-343 Inhalant Abuse Copyright Status Some of the information at this packet is in the public domain. Unless stated otherwise, documents and files on NIH web servers can be freely downloaded and reproduced. Most documents are sponsored by the NIH; however, you may encounter documents that were sponsored along with private companies and other organizations. Accordingly, other parties may retain all rights to publish or reproduce these documents or to allow others to do so. Some documents available from this server may be protected under the United States and foreign copyright laws. Permission to reproduce may be required. This is the end of the module: Please complete the evaluation and answer sheet and fax (951) 739-0378 or email to  HYPERLINK "mailto:Educate100@aol.com" Educate100@aol.com Key Medical Resources, Inc.     PAGE  PAGE 2 Page  PAGE 3 of  NUMPAGES 32  PAGE \* MERGEFORMAT 28 578Iz̷oWD4Dh# CJ OJQJaJnH tH $h!|h!|CJ OJQJaJnH tH /h!|h!|56>*OJQJ\]aJnH tH $h!|h!|CJ(OJQJaJnH tH h# CJ(OJQJaJnH tH  h!|h!|OJQJ^JnH tH &h!|h!|56OJQJ^JnH tH )h!|5>*B*CJOJQJ^JaJph h9&65>*CJOJQJ^JaJjh!|U h!|h9&6&h!|h9&65CJ0OJQJ\^JaJ0 567Iz   $*$a$gdu $$*$@&a$gd# $*$@&gdu $*$a$gd!| $$*$@&a$gd!|$8*$^`8a$gd!| $*$a$gd!|$a$gd!|$a$  p Ųs`O;''huhu5CJOJQJaJnH tH 'huhu5CJOJQJaJnH tH !h# 5CJOJQJaJnH tH $huhuCJOJQJaJnH tH +huhuCJ0OJQJ\^JaJ0nH tH *huhu5CJOJQJ\aJnH tH $h# 5CJOJQJ\aJnH tH $hu5CJOJQJ\aJnH tH (h!|h!|CJOJQJ^JaJnH tH $h!|h!|CJ OJQJaJnH tH $h!|h<CJ OJQJaJnH tH   q F | } %&NPQW]ciou$ & Fdh*$a$gdu $*$a$gdu*$gdu & F*$gdu $*$a$gdup q  - S T { | } X | ڴڡ|gTD4hAurCJOJQJaJnH tH huCJOJQJaJnH tH $huhuCJOJQJaJnH tH (huhu>*B*OJQJnH phtH +jPhuhuOJQJUnH tH huhuOJQJnH tH %jhuhuOJQJUnH tH huhu5OJQJnH tH *huhu5>*CJOJQJaJnH tH $huhuCJOJQJaJnH tH $huhuCJOJQJaJnH tH u{D*$gd# $dh*$^a$gdu$ & Fdh*$a$gduP_`gkpyݷ~j~j~VC3hCCJOJQJaJnH tH $hChCCJOJQJaJnH tH 'huh# 5CJOJQJaJnH tH 'huh# >*CJOJQJaJnH tH $huh# CJOJQJaJnH tH #huh# >*CJOJQJnH tH &huh# 5>*CJOJQJnH tH $huh# CJOJQJaJnH tH $huhuCJOJQJaJnH tH h# CJOJQJaJnH tH $huhAurCJOJQJaJnH tH DP`z:;WX $*$a$gdC $*$@&gdC $$*$@&a$gd# $*$a$gdu*$gd# $P*$^P`a$gd# noWհtcPcBcBc2h*5B*OJQJ^Jphh*B*OJQJ^Jph$h*h*>*B*OJQJ^Jph!h*h*B*OJQJ^Jph$hChCCJOJQJaJnH tH *hChC6>*CJOJQJaJnH tH $hChCCJOJQJaJnH tH 'hChC5CJOJQJaJnH tH !h# 5CJOJQJaJnH tH 'hChC5CJOJQJaJnH tH +hChC5CJ0OJQJ^JaJ0nH tH no=,^ _ #%'N*,0.N000o1G3450^`0gd}0^`0gdgd* $*$a$gdC^ _ :&;&&&&'****0044hCCEEEFFF(F)FzleXKh# 5CJOJQJaJh`T5CJOJQJaJ h!|hChChC5CJ\aJh\h`TCJaJ)h!|5>*B*CJOJQJ^JaJph,hh!|>*B*CJOJQJ^JaJphhdB*OJQJ^Jphh}B*OJQJ^Jph$hh*>*B*OJQJ^JphhB*OJQJ^Jph!hh*B*OJQJ^Jph45)89;=o?@BDEEEEEEEEEEEEEEEEEEgd*0^`0gddEF*B*CJOJQJ^JaJphhegFh`T^JhegFh`T\]^JhKhK\]^Jh]h]\]^Jh'Th'T\]^JhC\]^Jhi?hC\]^JhChCB*ph&hC5B*CJOJQJ^JaJphh`T0J5OJQJ^JaJh$h`TCJOJQJaJ h`TCJ h`T5 h`T5CJhh`T5CJOJQJaJTIUIVIWIXIYIZI[I\I]I^IkI=K-LMNNNNNN,Q%R*B*CJaJph/h# h9&6>*B*CJOJQJ\^JaJph/h# h9&6<>*B*CJOJQJ^JaJphh# h9&6OJQJh# h9&6OJQJ^J,h9&65>*B*CJOJQJ\^JaJph,hv,5>*B*CJOJQJ\^JaJphTTT U UUUUUUVV@WAW^W[[[B`S`)a1aDb󶦛m\G\G\)h# h9&6B*CJOJQJ^JaJph!h# h9&6B*OJQJ^Jph+h# h9&6>*B*CJOJQJ\aJph/h# h9&6<>*B*CJOJQJ^JaJphh# h9&6OJQJh# h9&6>*CJOJQJaJh# hW>*CJOJQJaJ#h# h9&6CJOJQJ\^JaJh# hoOJQJ^Jh# h9&6OJQJ\^Jh# h9&6OJQJ^JUV@WAW^W_WiXjXYYZZ[[[[[^_B`)abHd & F gdv, & F  &dP $dN & FDbbbHdPdgiiiiiijjjjkkFm4noȽq\UE88h# h9&6OJQJ^Jh# h9&6>*CJOJQJaJ h# h9&6(h# h9&6B*CJOJQJ\aJph,h# h9&6B*CJOJQJ\^JaJphh# h# >*CJOJQJaJh# >*CJOJQJaJh9&6>*CJOJQJaJh# hv,OJQJh# h9&6OJQJ!h# h9&6B*OJQJ^Jph)h# h9&6B*CJOJQJ^JaJph!h# hv,B*OJQJ^JphHd2egeff7ggiiiiiiiiii$G$If?kdQ$$If***4ap yto $$G$Ifa$ & F iiiii+fkdR$$If0*T *4apyto$G$Iffkd5R$$If0*T *4apytoiiiij jfkdS$$If0*T *4apyto$G$If jjj$j%j+fkdYU$$If0*T *4apyto$G$IffkdT$$If0*T *4apyto%j2j7j8jDjSjfkd"V$$If0*T *4apyto$G$IfSjTj\jajbj+fkdW$$If0*T *4apyto$G$IffkdV$$If0*T *4apytobjkjjjjjj4n5noorrrr| $$dNa$fkd}X$$If0*T *4apyto$G$Ifoorr shskst!t9t:ttuuuuv}v4wCwxxyy{||"}2}{}}}}}~~~m#h# h9&6>*CJOJQJ^JaJ/h# h9&6<>*B*CJOJQJ^JaJph#h# h9&6CJOJQJ\^JaJh# h9&6B*phh# h!+OJQJ^Jh# h9&6OJQJ^Jh# h9&6<OJQJ^Jh# h9&6OJQJ/h# h9&6>*B*CJOJQJ\^JaJph"rr s!t9t:ttuuv4wxyz{{{{{{{{{{{ & F & F & F $$dNa$ $&dPa${{{{{{{{||"}{}}}~~~~~ 34 & F & F & F $dN &dP & F & F~~34_a*AB-|~͈ψΉ`Ȍ،ٌԼԼzzԼzc,h# h9&6>*B*CJOJQJ^JaJphh# h9&6OJQJ\^Jh# h9&6OJQJh# h9&6OJQJ^J!h# h9&6B*OJQJ^Jphh# h9&6B*ph/h# h9&6>*B*CJOJQJ\^JaJph/h# h9&6<>*B*CJOJQJ^JaJph&h# >*B*CJOJQJ^JaJph%4a*AB,BUn~Q & F  & F  & F  &dP $dN & F & FQ~>ψΉ$OmŠ' $E`w & F & F $dN & F & F & F & FwȌɌ،ٌENZgpwُ% & F & F & F%WGl֙GZ?ɞ3G[ӡ * & F & F & F & F & F & F & F$a$/01?@DEvwxp\&h# hv,>*CJOJQJ\^JaJ'jy[h# h9&6OJQJU^J'jZh# h9&6OJQJU^J'jZh# h9&6OJQJU^Jh# h9&6OJQJ\^J%h# h9&60JB*OJQJ^Jph'jFYh# h9&6OJQJU^Jh# h9&6OJQJ^J!jh# h9&6OJQJU^Jjlԙ֙ԝ?G[ѡӡݡ (*: oyzͥץqvw˦̦ ߵ¤¤ߓ'j4\h# h9&6OJQJU^J!jh# h9&6OJQJU^J h# h9&6CJOJQJ^JaJh# hJgOJQJ^J#h# h9&6CJOJQJ\^JaJh# h9&6OJQJh# h9&6OJQJ^J&h# h9&6>*CJOJQJ\^JaJ*oͥqըʩة+4HT & F & F & F$a$ $&dPa$ $$dNa$ & F & F STը֩ة)+24FH8:PRüÝΆnccccccccccccch# h9&6OJQJ/h# h9&6>*B*CJOJQJ\^JaJph,h# h9&6<B*CJOJQJ^JaJph!h# h9&60JB*OJQJphj]h# h9&6U h# h9&6jh# h9&6Uh# h9&6OJQJ^J!jh# h9&6OJQJU^J%h# h9&60JB*OJQJ^Jph&:Rͫ߫ "oTq & F & F$a$ $&dPa$ $$dNa$ & F & F & F˫ͫ߫ "moӰհ)LM3CJKpֿtbQbbQ h# h9&6CJOJQJ^JaJ#h# h9&6CJOJQJ\^JaJ,h# h9&6<B*CJOJQJ^JaJphh# h9&6B*ph!h# h9&6B*OJQJ^Jph/h# h9&6>*B*CJOJQJ\^JaJph,h# h9&6<B*CJOJQJ^JaJph#h# B*CJOJQJ^JaJphh# h9&6OJQJh# h9&6OJQJ^Jqհ)LMCra¶ζݶ) & F  & F  &dP $dN & F  & F  & F  $$dNa$ $&dPa$ & F & Fpryam޵ݶ').8lt79<pepeWְpeepeph# h9&6OJQJ\^Jh# h9&6B*ph!h# h9&6B*OJQJ^Jph,h# h9&6B*CJOJQJ\^JaJph/h# h9&6>*B*CJOJQJ\^JaJph/h# h9&6<>*B*CJOJQJ^JaJphh# h9&66OJQJ^Jh# h9&6OJQJ^J#h# h9&6CJOJQJ\^JaJh# h9&6OJQJ )?-9<%j & F & F & F &dP $dN & F  & F  & F <= <jL[dfhݺҭr^QQQQQh# h-WOJQJ^J&h# h9&66>*CJOJQJ^JaJ#h# h9&6>*CJOJQJ^JaJh# h9&6OJQJ h# h9&6CJOJQJ^JaJh# hSNOJQJ^Jh# h9&6OJQJ^J/h# h9&6>*B*CJOJQJ\^JaJphh# h9&6B*ph!h# h9&6B*OJQJ^Jph!h# hB*OJQJ^Jph mjPx$< & Fgdp & Fgd-W & F & Fgd-W & F & F  & F  & F $<&QT~Ak^_椌tiUUJUh# h9&6OJQJ&h# h9&6>*CJOJQJ\^JaJh# h9&6B*ph/h# h9&6>*B*CJOJQJ\^JaJph/h# h9&6<>*B*CJOJQJ^JaJph&h# >*B*CJOJQJ^JaJphh# hp OJQJ^J&h# h9&66>*CJOJQJ^JaJh# h-WOJQJ^Jh# h9&6OJQJ^Jh# hSNOJQJ^J&WvQRSTco~A$a$$a$ &dP $dN & F  & F  & F  & Fgdp A{Z a^_`abcnoz{ & F_cn&'гСtiXiA,X)h# h`B*CJOJQJ^JaJph,h# h`B*CJOJQJ\^JaJph!h# h`B*OJQJ^Jphh# h`B*ph/h# h`>*B*CJOJQJ\^JaJph)h# >*B*CJOJQJ\^JaJph#h# h9&6>*CJOJQJ^JaJh# h9&6>*CJOJQJaJh# h9&6OJQJ^Jh# h9&6OJQJ&h# h9&6>*CJOJQJ\^JaJ h# >*CJOJQJ\^JaJ&'8HY & F $If^`gd` & F $If^`gd` & F $If^`gd` & F $G$If^`gd`gd`$a$gd`68CFHSTWY<34CDhi㥐xgXgXgXgXgXgXgXh# h/OJQJnH tH  h# h/OJQJ^JnH tH .h# h/>*CJOJQJ\^JaJnH tH (h# >*CJOJQJ\^JaJnH tH  h# h`)h# h`B*CJOJQJ^JaJph,h# h`B*CJOJQJ\^JaJphh# h`B*ph!h# h`B*OJQJ^Jphjh# h`U YZ<4Di~qh *$[$\$gd/ p*$[$\$^pgd/ d*$[$\$gd/ dd*$[$\$gd/ d*$[$\$gd/ dd*$[$\$gd< $*$a$gd/gd`gd`:kd]$$If{**4-ap yt^F iJ^_hj}euMY<}~ #CDƿƿƿygYKh# h<>*OJQJ^Jh# h9&6>*OJQJ^J#h# h9&6>*CJOJQJ^JaJ*h# h->*CJ KHOJQJ\^JaJ #h# h`>*CJOJQJ^JaJh# h-OJQJ^J h# h-CJOJQJ^JaJ h# h-#h# h->*CJOJQJ^JaJ h# h/OJQJ^JnH tH +h# h/>*CJOJQJ^JaJnH tH $J^_ghc<K~$a$gd-$a$gd-*$gd/ S;|,K  & F^`gd-gd- & F^`gd- & F^`gd- $a$gd-$a$#gvc4)x;$a$DIKdi#HIBDWXe /_az34>@Ss#M}?HJYʼh# h<>*OJQJ^Jh# h9&6>*OJQJ^Jh# h9&66OJQJ^Jh# h9&6OJQJ^Jh# h<OJQJ^JJ=gh#$+;.49Y[kn   1 5 9 G Z          N }      h# hOJQJ^Jh# h<OJQJ^Jh# h9&6>*OJQJ^Jh# h9&6OJQJ^Jh# h9&66OJQJ^JC7n G  :            - . / 0 1  $*$a$gd<$$dd*$@&a$gd<gdyTgd     - 1        ˵zczIc0cz0h# h<>*B*CJ OJQJaJ nH phtH 3j-^h# h<CJ OJQJUaJ nH tH -jh# h<CJ OJQJUaJ nH tH $h# h<CJ OJQJaJ nH tH $h# h<CJOJQJaJnH tH (h# h<CJOJQJ^JaJnH tH +h# h<CJKH$OJQJaJhnH tH  h# h_LCJ OJQJ^JaJ #h# h_LCJ OJQJ\^JaJ !h# h9&6B*OJQJ^Jph1      &'(KL$a$gd7h]hgd7 &`#$gd7$*$^`a$gd<*$^`gd<   "#$%&(-.4567;<FGIJKLMPQhiklnƳƳƳƳߑzkjhdEUmHnHu*h# mHnHu*jhdEUh9&6hdEhIhuOJQJ^J h# OJQJ^JhmHnHu$jhIhuOJQJU^JhhIhuOJQJ^Jhh# 0JmHnHuhu hu0Jjhu0JUh Djh DU*LMNOPmnopqr$a$h]h$]a$ npqr!h# h9&6B*OJQJ^Jphh Dh^F 21h:p7/ =!"#$8% < 0 0/R :p# / =!"#`$*% P < 0 0/R :p7/ =!"#`$*% P 8 0 0/R :p# / =!"#`$*% ?0P1h:pW/ =!"#$% DpFpoiwbJFIFHHC       C  X "2B#Rb!3r$14ACQScq%Das&5TdtE6<!1AQa2q"BR#3b$4CrD ?(6xMnGV${ jSgn>(=~8X~ "?ЀmcAT/žУQ(<}:Xa₥]c30}>d k^֨@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@A?~A 5Ixsf `u#(s]w1M0QGL,xJW\nuBcYiRz=n61V^.@]lp-f7F-ۃpcp ר| j檲hL\MΫTƿ> VU8@@@@AF#YcqAJ7sԫV |M|L?]6i~M+tRj8|U$JXq%7Xc m }K>*V>?-P빍@@@@AUS)m';cmh fUު΍:[vxyXv՜mZ5y8`s8|h5*pڱ?j5Jo+SjH%UFHuV)A}FjэJ&Nѳԧ55 kHzmȭćr٫9RSD+18j4N,yU|mGmH>"W)] !/ڪ<˅%rj3x2uf՚9;^:T\S n 37l>{UBQ92@$<n{IUKTa?N#Cn?)j7xΦ· Xwyzv‡5"s9*!:.R sZ*Bs;h4WZ9䪍k[Kyv_/MIWkIweRWei@AkҐJ.BK%ZJZB696V&#10qípTO/l~>m§U%z}X?g_Ӄ:Kij[Yi~ilpW.sN ]SϿTO嘔5OxlqK׭UGs#_O=r$:]aQ]>dxV*}8Óhj7{!eG5OhS&͵iY9uFps-ǣ]>NJvRkp¨Ǯt?`q5UUKx\2D^Fj)5%UFH%RWJ[t,,Vh]eVQ."+VXgz, mg̻L#UJ] v;Ӹ]\>ҍ3LQWWeߞdY^Qs:{twT뎱Q;s\od\M&Gi ͠]cUsa-g,D'2++%=WztF^2WƩ*tFXQI*y N[U9b>LF^-ia>W쳛2ioJ߬+gѝ*EmZpb/E@@@@@@@@@@@@@@@@@@@@A0Ps*MD0bԭVCM!dmU]2%Zk3,íKbU]`/\]% %\鬓B<597bN vS(M<`>5::|\ WO9W]/Z'M+t:Q3t iwYEN;_[+}UVUd4e !jJ:Fa0j\h>ꞘwlWBG;VljyiVdʣuwh0,^DyGJ]Ol<D>¯íUmҟ[lj8Uj\3M5lh_xzHT|$)"&{(*|舰?-X|6gGV~e1RƤ{FDĴ%~'9!^MT6Yz=7DUeo }t[ u?[8OW[etGzaGUUJ~q_;jM'eq"wڇzTs˰G޷W)m,搧ѐivASHS{:c-բP-PXYׇ(Mf5U#%wM)PTfTXnM.& (rTfv_ܮ³>#ĖLClPRH$l. ~増EQxaُ{RYrl3kCtdJWsv@d e1^υifvdHTX#E{_K{3xv~T{0N6ե_򍽗ձ@ߺ)vfWhZR<$Z{g/\ʟLz`]/Z󔘞PL!!%Īwmfrev˦kNSEQjE.aPU<;e*1*Ι 1WD!ԋCw~//.4k5@ ňp:Kj:KK~%,i:ҖW" יe\xŶp₍W'bѕEߟO8keVňQfc[ R ЧB섮uѦ!3wӝ d 9.H!ݭFTF+=V+V6t(2$xt-u4Yb6\1 G-˙6mza1G}& n% .|jեB]gzU. ]+`ԇa#6^/1"c>J^3J<|$vKTgukSՇCym(qMwU  #S)T,@e4F~˪fc?-|>l""^kBj4{]FJK'Z7Y%J  O[VYYx)E"']ªվݗ;V^c,V XcC%^퇒 s.lyd[*[Kn!L@Iv JbSf] ApK["@ճ4aVt~5Ì"r:91|:.ỗPܨ|q)鎱9s7nR9]/w+]~Q!eqqiP$tαyekzR]]2(=۾TȽɮ"p g>;;l {ukhR|c {J{vbbv<)ìvVy˔|)΍FDzu>?b5*bRȋDH_Q{Nv~\OJna3Zr)b2@dѰMC"."[xoVLsѷpӖ^3=c0ҷ*:1"lJ"ZS F~jO\>efrluT@dAD%qq9+sj H_^sVf ]۩+uxvĈ]pzX/w%f0+Oš =fJ* KoMYB~W-&afkXaRGRb* آ AaU9cK7Wb\W캔Hqs7:ŧ i -ەk{t f93>[YM"#å++jo;M꼹HQrJi\~t _KQ#/'[n&:]nWGq؞StfH|mgyַkwYOO'lάb:5Wn`F>ɭRlyÈZ"5UĨԞTxj3|{K@"u\-xW="QY9d\g?w0)y)CgUE>+ʱ*$>6P}VkY}p - GTQ4+ȝjthWl S|b#苫Ek*o3tNU@-Dt#W4ZN"J\URV':DqeoJ8ѺuTLӛXt[5xkVI*LN +n[xOʫp=dJd~40DݩlDupx_JԾ ջPDݾlj6 RGb~Rj<[[{Vnm%]W脩dDjy1.PbUgkkvص,b`V{d‹DYUΛ!u"']ŋ!/l-syt'ʧжejbm5r]=*5\ őUm~8X#Œ6:xtb4ӼG_Q]ަe@S&5&w.'SE(DIEuwjy1m6ӡ\EGk˪h(ҡDR*PdBi.jG&a:Lm.{J9;ny[5WR; ez!IܶS|0Ub)XHTE_|f #M Pd ^hnbpz,Gz8}% FGWs|}_Asݕ*|" !{R$RC(}YV#FUya~,p7*jL@Xx6EtØ09 nF8ue{d ©4raWZ|=OWFk2Ѓ.ORFaF dNkԺﲧ\9͙J1AF":LF/_Y}VׂV|5f4DJzq2"c-̷_tڶW#¥h'c&w޶_1>K;0e[\ 9} U-HiFꎥnGTu^'Lu!e]vYq:DB$9mwnhYkevS#;5Ϫr"^ܳk_+OfCQ KW-*ѾnDc{}\8Pj\Ej>]CG e`TǚлL@z*k4JHvDʥY~1ݺmKpv^vvU~yUzDGa΍B;m%wuX0Ukn3=xR?{_kS$Af:f֩*-5 VPhYuޫjD#{GS_j'`ʕE@GivTwѵyĜ-iҝk/Pc2N=,wW3|L3HE} ̎Al:}Җ|Q1?Yfڤݑvqn+$>ʚKHEz[PZ9U1> ҇N"+_jXp>xjڪɬlmijngZ/ҶΏdשׁҶZXd;CuUVM]U-Gv! 莟[r* h_d.Rm|8B˱f1QѵUj_+;cG>EjU.L9Kk$'vcҸiI(ǿkR7e6\iPwe zuB&ݞ3Fdj1زZ4!(wH6!kH4A+gc#^Mc4T-GHZ7E^aLd$G1uuI1B$z7N9J}:e\N{ {G 9|Y6i@kX !kGqSK=):]_|3,>/ *2J;mĴ\RrG ԰wSGd^6ݏLOk%a"U[/ Yđm D>*-\jJĭ` 56kR7E[]t&X@Nx՛./ N%^3 (RwJv.죖w[VzF>tm\D}zx5Pje¢I5w NS" [!ڰۺ A{^o}9&1v@#Wc]3,QGH}qoU<7Nu3 {$pH+%u<^>ř ib]EJ'.t-\.MM=֩ռEéZ/_X[ a`ˉ2 ?a:ǯςإ$)C8w\.5w<ݩlKiM:Mާ*ky)K?ryE:Dɭ-wyH T/QԎp3Kc^ h3FwL6Z!QXD`>pxVdզ:QỬ+v?=)q6 h\PLuv@weى*lvoC4<& F>j/]\:fjXАw:&Z-GboUly(btxi_z -*[R+dvD%0խjyX?DGzo|_.=ğ6gwڭ|pe{Ps&MfdҶj8ڣVsֶ/zXf OdoQw {T9ߣ>fh׃<G*_ +o.;V[ }Y||L9J1L 6R}hi3UM?wjЗ;i[mC:e 2[?fg7vKORTjeZml9&smwTCDTX(Lz?ZA|>ċZ0x|\.2#=p~,G2=ylaƏ P|%>V0-t]+V:-*d*kTH*dCHH>=e1#cAmq&LWj y$c5j-[0쩺E<E:Rl|B nmsJ՘o!ֿ#([ao.|7d9i])lxڨ9u9}'G<鴊#w3uWlZ2rCkDT`G"޽ViٮҝRj=j:_O)xcIxØaekx?&͑uKh6?H+8W~nH~)ڟ,]dϵv!q"_yExo[ryxَ%e D?S>?76<34[K}ji[l;"ko|3yʿ**Q7jţ.LupVaM1"gB[8B}!u)(7(EH>ydVfp6( ߍ&/hX}xrL _J.;o4'/pNw|SR:/j/O+DmxSQ5J5RPVu帆:ΉZ:ۓ\X GB}Wq΍3uFbyQRj W]a^|N%K9#Ƶ+e&=;Kt"笪=)\vػPV¼;?#Os*v:]<-QY: 9?["2[Uje;N(&*m(w¶t>g 12=Z}{5to^zkIH]s p=WᯗXv( ~Q+*\\H`RYߡuSvmՋS8bw*?,yqyt;SE wIU-yX!ƒ:vHxZhH.VG˚ovA.=F.4}U!h̘C[Z3wF84ud{!ҠzTcvE{Ϲy$y;0YsWZkeVK$ҵ iWhqb$~:͏ ívJiJF|ͣ:bmSimENn\)عlBzu ed雔^1\V?h(d$:,;X e1xXkjj l͑yprat[ Π8w0i!/ʌT3t3*,MriUUn4.|ﯵjE>d{HLs3kRң]WJsB\2RÃe%WUGfJ:KM#ʶacl;:Go1++\-:"Re?9,M c_m kbd"*DeͶJZ~,OCv!x^R::Il >87(8 k8QeQ*C3 -r'ĘX2OHHoT&xYؒ“m]>ȹ NGDk̒!>MM!ܩ\k6-8VsgcZEUOK8چ s*ʃ ;[Ă7Tmem}J.(#=B84? >_/;X=< HM>tҝfC$AKfhyؘ;VL0]/KPgW'm^-Yx<>KazC"fAf(ʷ5gtX?x~aZ.߯Yq76H5{x]GG{<%v|gM} cѸ~ǒ!o4}!V}a/ᷙ'yt Jd)ұ~ޡ4ö+t= eG>UF$^3ۭ3% VPAkfn`:f[T{x0j)5ϑHꞧ!ן;g|~}n| jF6Mr""mmAjNêa"X|El] f 8ys Dc)Ұ+Efx%6%ǩnkQA'=֣oXIcOWzc6zY6 \υC2tJ4 47#XߊhtGT!mvED }>0jDGn".2TxKGvG=xT18h٧\y@ը"xHwl᫅eǵHc;hd5ڴZ{Z+eٛNDO3I~"S J!-G*+-^F[vq,}STga_k;UmW(ڎ۸Eg-eO,|!2'~ҳy[1d&z퉝=wVgGEȈ_DVH{-[it NY|p+]oŪ.ꆯ,8s3a{Ӡ48e/ ^wߤ$6%!6Uv')E!DV(sT#C!Q[8s;@,QHnR '͏xNuRحUjGhj\I!Ok{Hz6c jZIP.61}":9VꐦZt[a+㣗+t9[X o/[PUQ] oS*J^o1D{~ʫ~.lޝ$-F~.QS7,ýnԬڑYpi_$eC)줵*EP@+̭ԎBMǩNuݬHmłWTAZvPq^{<~ 暐ǏjVq;{\=:ןgv _UyښVDy=՛5^ D@;"Ҫ,/1R p1@/ƵB'V)Ewh_iJG=ڍRⶎH'RaHmgHj_*9]TTC#f?%I1vӎ4\.4\BJ?Dcgx+e7?Yd{x_AzlM &S`BkIBLw2E쒕js<7gZAvx%}3a4iNn?D* u[VTiOe uĝyә3 :<_~UZ>8ČrYlJz|*&{_앧`-nKq9*~kgd%N2$ OꗈUlxsIܺ-#)~WUSя=Mч[۽.`ypJǒ aֺ65!z OVDffcsn\zV>F!h=f_?z:0v0ԇc[QTS>Wz=π5 ִUf)*'C=]h?֢HwBOG!@,"O[vkciuqV7D˦νw?|KeoKBv+}axPW@ 4֝}_Z$/Kiz![b2JsQIvls X1Nx?k3+u!ՏRׇU6z1bNka$^sR[Zf_?r$kA^g Q5m[˔5"s*-UʦwkR !ժUJSkyĻJt.QJOkdm7]"o_WRd륨̵ ֙븈7hԙ5J\K)}Q/u®sҠh0ڊƘZk5QUkSWA!z"@~`⻓萱,pV̬֨4gZkES+4etB 1IǪ ivɋ~Fl~*¤ )vAiM&Z{^dZwewġjmFkWUB_$P^X #*U-gf~w٧(-%uZ 5[{Rq*nd}Xd</x- Vkt}:OS.XZVKke'ne"hk5ĊY_u^2]k)BFapMx[= eQArj|ʖbFӿ!j g'!G*T9_W-nM(bU,7)vsTH"ڇj^i3dw.>$Ĵo\+ ,ڳ/m_o q Fh}I;'Ӥ vuwjޭW>{u x ?G=|зHoEl|NKLylNwvW_Yd♲^X.ZW(j+Y_nɸF0vq tTYLNpfa_a9ӷ\R'D^?SFSc([xYmgOj򡡼GgO"$%^}\.. H5<|-D]XズW6YMjeaV .ޤH3@@@@@@A=7Zat0a۵ze5AGJaKdS>Ue {QԖO嚸M}Yb9(ڠćhj?\Ղ[/o BDs{JNA7&UXo8y9nPߤ>_iF1-˯RiNGTZaEǁGKj_i3L.>@QIUڼ]A!JHv!ɗTPYlq!U(]Rpë~J,to6D,Ix[ȃgwBM=ndt1.YzA:4Mxƫ5̃r*zh.ۢSvc}m.܋bvH9tmM=bbfZ])PMS.@y{+G D?A2.̒H䋲ktdUN'̪LCꐬMq]A 6O-wAMmdkMSQ4BD,ATc$5-Sk.Q]_5=0 ~ Cc*dUAtwwwyt{U Qamz !zxAHdgDM"&GU^ee6˨5G > AǗ̽:2ٶAW&Hl{-ëk{\FlCb׃++N٥Cy 5p"n&oײI52.8 ѩ֤]ɯXLmT,WݹV<#.>T:!rADsH\%2eb{}Liu(#L'2Q*p,B s jV R.uMd\*|"_\ȮYnryc4MNu#B^qwdTztoІbJyǨߎ.eD&L^8|f_\8&٧X4!J䶮˪Hkqmz fD} ":[cw"k?Ю&׈oC{ȃwg´a՟) mo.}*Ӵio'}kWW|3Yc[5h(Ûݬyֳe\JE@wKGZos34(!UZ١cf)Ts,ѵe^ǙhNlfk~7nZ7Eݯ& WjQuCk5Q|Wu :A|!UA948eupggZGé>,u!NDYllUJ|a£l'bTY;ITG+9q;-g,IQ\r_-cR3.QUt.zQqjNcCGּ|b6;rcN8|1rk橹F!lzqqUjY(rDhڤb ncq!׏S92Rp@@@@@@@@@@@@@@@@@@AU7XU a^E7ns10kzȗ2\&C-XeYmŤZv t$~QK+T~'zG1=;Fmo1|4-F \^-Hbriq[|?؍wErl}RL|OX4o"*r7KK/cfNٞsG35Ld59epjXru8ΟcS}*>UQvNk0cEwx싙hEL'~%!.pn'y%-HZ'+ ՚/h7LGǫNmպ,-5U&k4FQvT?̠5/Ywuʑ!2<ƺ#֊UL.8کf'vBME"J۴v-<̵ޥd`h<\}(Sba~9z6j; 9OU6' 5]UFEW pdcz2fgk9M{G-&b~T9q+&ՖQTUjX0Z9 |_0=aHCT~x*1Zm97?Y_L9N2+CW=(4XمPE@L;;3^sߢ>%P0[Үp&itES0,| c=X`eڻ΂peofV&b'h-q8)Ue+?8cd\?QP*J@%UTvSF?IVJ'M^˜{[IfNy:S_iAh{JK`KilZ.nVa۳w}GveFDX"Ϻvc[XugS9rOH'ő bOin>UsLʨ2I#2ԘvܫpxyUU}]=FOh-1ʳw[F-\vYCl)l*TTzt[!?O66"J{o [#:zGDКrjRm0N |\DVwTTVԮ+P]&U!+K\ۢeiG{"p~XARY˵+H_Uvc>BVӥFUbV;RBؚp/k{忌ww"y}k1%d[maiv#+5%w k1?.ޯa$X^!>qe1Î1k7_>6F,bPMG-㎦1Ze7Yը4&ʌ;!D_QK0k\ٻqa˴\ҷUa:[ 3vR$a2fg(nbCQ[.+x]fɭbǑj<" &G`6+;ki;ϙ΃9ކ 5e_j-moCV#yjEO-ԥ(Zq [M[HWKow|m?E)S'F]>UNӮcc`j"lDUiK~bSnUGSG8 [+l ^#vQl;uv6&淙E6V6NeUObԛHͧål>(eS d6'8- jzuUcy_)s:EH]*+Rvѷݝ+xq\Ox¤mPWŠV>7E]Slˤ\ײ~tql! J=v](aR*Prn=5vc])2;v\.d~M1u?L?daz/1 h=u>/מB%sY$[zӄgLZPVU 4vYz]دK[i.|&^qw^V1Djӏ"8u݆ZnxGD;#?ԙu_*Pi=ZxT% zTw(ZR yYvȌvCvEF<p5I]68+n-=ճ8whN?$dI|7y kěIj՛Ƕ[]]&4QlIt 杶mU9umVܺ^)*ٚo%B3>n5,י$VvE -AhܮT#~6LBt7s-Ӱ-iTюʏ0W.U8EayMbhN>#sWkwbosfYF<688O6Vڽ]ȍlm4Kב=rEô.K}eEk>-gJ΁VMTj5:!:LvPûd֑W/FStzGřR'Geei R5*s3zv)!#/| 'w!{]쮹GU֗ׯط>{熫:[[X8eXzFq#RžGhE}Ct\J*& H2m_t.4n{VD@]??O?zFO]3˟طW$ZJAi :&::3}x*!std1j)jTǮ7\9b*ɈOگϵYZr6uV*cks YJ'|uUr[Ss\J;DMTNߢO)ھZnrsM5:2Kügiz{50ҏ #ul;t~Wm7]L%e2ӛ`L4R a::;Rٳt}Um#\R-%,]smZbҋ~'WU7m5h﹖ z`GsjG6qv+J5 )UJ2ȟBD\s˳垓r^]TƵĐbmh;FGy!o>l͞2|dPiṊN7D('[|NoRJ`~/?Կ>{O[uHUj<`6Z;RmDWrͪ'O.,_1&:Gd}eT|EhW grD u~vyRjAܺ,LxѺtЯpp2J6aPɥb"n =Xaco_s!^T{ lLļ_3U# !AHd5Ձuc`\"dtE1W^:uᇟOU*)A-(gw^?(sH  0'Mufxz0'kf~XV_R>EN2V<4X׀=_ι13w?D1yE=F{N2@A͇ DppO2 E4 v޵ ÄKLrW |GQT.r|m#*?=?u~:sjj,eɈa!H.[˃a8&]z c$<8`>~b7֡82ssEHgOUGT"*z(˲Zeo 4:d~p\}L\ԋ\'xP>jSP;L4ʔ,Ŧ:w0K~e[ٴ$>|\ЮJE/Cmi3)ec 0,KW4ㆡD [y@ (3@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@Aq @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@AS)cu8~['bN0u)055555>DAAAAAADDDDDDDDDDDDDDDDDDDDDDDDDDDDDC  &&6& &6D6++6DDDB5BDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD3"C!1AQ"2aqB#Rr3b$4CS%-!1"AQ2aBqR3r# ?:꼡sj.VX֍%_' -o˵zb+<'/1- Bw$-Mȑ*yB1pQΦ_W(~_}UA}~[f:!S{xG[LUSǑUusuq]EG7Ro\>ţ+GC sW1I#Pk-؄k?KJs2[Z`lhhDn"j1pVGP;R@wv5`)j,y,qEOs:vOSfEYqv4+ݏBENCKx aaEGsùN@ IuKOUW;P;|՟][!!Qj2WFS zgesH wYst?+</piѼRκmU"'(嶼TLcz,| ϵȆTِh#U&LY;P1Z嬏١s;Q ]or32'UC0w{毩F(1L).r 2]nph.<Q&u+s"I:9wc :ZͩOguV4UPF Z^t^}Ga 5YcϕE/Bgd}-'NK伏xx ?3%_K; %{aѲ>Hs6w94c92kdFY%Fu3Q^;B׸l nIpR)j8pt.Y{2Q!&@ke&e-^~}CT{Greն#< 8*f/YT,3̫BtsCx4&RSMn>H:7Iw29}W٨Zw0wN;<*Y;uv)~-[갵Q_/*+=fQ]=RH&X_~4Ǥ:{QfxW˹9^b(X7[X%봹~5n|?9/Y\U7q ծ߸+b7,:q#ZEsⴭӕU^NɴNTc m !kv/`{rT>oZ>Pp_5Xp9!K4x zۚ C0Eo9GqN8d`X۸.8_&nE|oVWtMgoysLm`E}O 2`vK5_T(|,G 穞%xr*+Ռܱ8 =)C5?GBGe#BR%x˚jK($:h֓( GWT Z7^˟UShFԢYPOz_l_50yش;aSQ>^Ԕ(S}B#sQ3nTtRs[^{+Dw{89~ ү]O2 <'K %_⤠1\q%%2dN"9دf*dq<2G } <^mEjłD kӂHo RG8^ҭ uKrd8ڐ8+o#WicQޕqIbZ̠pږ[cޖcUDFxs[잏LNyX6-}⼐^fqyw `Bb+1U @M0Mmow%hc ti|梞JY R 9ˢYZ6CћNf`x,mֻ:w䛙Dy?T9sE?O eu+~% klw:HG=/p)Ro>_s3C7X`ºћe&F4 al/JgV-0[ ##Fn<ʖRU?V'gTŭ,,5y{G ]ACҹ}>VV0џ1%6 #NEI- f@k{)jhuv:]]Lb@}wN\W*hp?ա6f kk!wH)gFkӾgku09[3NW7[V P5!i6aş[Ev[$oSxCIYQ{8CV%$"ff}'DΥHY)ߓѲ!Q6p $Tx)Jw+7ꦩk{l*jf1 7d80 ΡU@q^};IK fpV1deSҹAHV 5sU>qTn /mBƜx&]Ia=4 t&Ǐ#VdmlQYgŎŤ\YK*f\umpN2\\LceXld tW&ii=lm2//pOBNͺMNj[Bl?`'UWt(Y|J@gZmg,a4Qns+STH^eNXp5z7]/MszKrTQ7=t.:QK:>ieeAZwǞWli\N,*;2ݖP8Vun;~Ku<xutHzI%&O,4G4Sgp" y9ڒ8,֫udb)msulV~l}w]k'; O-{_ьBVccY~H7us0@ HQԷ~A*mn;|}Q=e;Ga'kp j)YAn:*:DbvQ9-]#w ?-=+IaͱjDsF짛If@l~ST#Śjluj@{y4ՋӹM.:H0ЍNT!?hꬡ4{|2r@cr3曷+xfs^eZrd& %pR:5 rj(6iݓ*%>j-hf~O[U!cj~7WyGE/}Ty^Q6*2S eӃʎLb-jskV=kGoJ?ʛcQ-:|>*T *iPwa :䂣?Hq#6)bζkkID^^ɹVC-Oۧ> CgUWح:G/Eu~~EMi8BNݾJ3xljpTTm3?d'98FPX˦,?R6##Y(hklUž }Fǂ mor?eŮZ$*br[S}+ks7Oh'M`-tgU+ Â8c(p]FSmG31Fx%Ѱ#GUj tw;-Ⱡ啚G>I] Tp<maup~:u9eEj^~^ճh?4U1pf#N"kprVR\g'uUTZs6R74t}Z03;2򀨖tE%T*:Ps}O*T\B<r=~R_gx}BՏ ~׺ކˡ]3tR;jiGǮ*.?P)HĨEw!3z̠HTX﯂J4xPu~Ny ت6 BeP׷,Gmn%U ܍sRѿB1R^K֏dɔ:ۇrxi|ѷ(%Kh>7rEJCpBKFJ#z[/WO DǻS5 TdN!h7|Z{NmK(uЫhqIp2v>/CV\Dۙ'EG7m> (cMho%gZ U}?kɧc{˝WIUo-4enL+v*c)06кnˢxw,?uQOM;XQn-bl>;igi63+ /+]URɚs W>rU,81u2{ekQf;+,t+5Sc"ᎌuA\c*,{A܄c%q2{KN|6it-M<6H|Tg%¬;Hx*2TMvn^-%t]!Ptrdc$U#d>˼X[]N&\Q@p>J3=SF%T|D#)k6JZ4..?򨒢(n6EͼE9Hܠ_ެOX J.¬Poqd%vqu?RZ͐e*}!7] pե- *ǵ՟Kz 7M*OR \xSwj&'CEnrRv;b^, Tr3nF4u9^6l!ֺ:wuF>ןњ7MU1^VUHZ#sYZJqvFN jY 6(ո@Ύ-x,BI?mܭ)*r`lÒJJXjz'?jƱU ҷ:+Q@:|˛n/eaZ waO88H oC-+\ZnI揪ÌR=mYhu" x@+x>E\Iz^u467yo4M&" ̚8_=ȟG!1KtKu$qpr ̣clB4oiw.6hv}zRy4zX`-(j9j6aiGYX c8_WT|vbX\~K֛~?g}^^K?Nc:H1hƫ{dQ#ˬ%^_¢HvĨzUZٳtV-N?k/nO%\KeMTNgA;-^@BSFD?a`n~G4[?OqL9 ?(2?>i;wKp\Ihc=GuwFNZ9)KF?>žk%Jv֍0#C9[5]vXQoE~Jq%SӰct\,b p̥Tп1dMJRzN. h5Hlv] 93AzFQ>e!k 2sN*V6 c16M7G#aXy:G7+pچTŔ MìPl< HlS&E~(N ]~Ic%KB[dʪ@hl/z3 )213P%QIˤU+سI d<(xkGzIcEa.<$C|me%ʐx`oI< -ĸ#o*X4}s)62>7DSz*pRcOpV{m$4h<54 J#T>EcGIvh:>Y0):9g Z)Uz[Ӵ"rAk o7J$3a[Too}V;(Lk1(gIa\megJym8҆ *Aۢ N(_DU7xĢh*{Kiޒi>;$;d?|CGKF/U.oR_ yt}4RB)RNWQalH]װ<>Ԭ|ktARUR1e@PWNZ֑UYQE3<5wTZt~ .퉻z=;+OK1te+d 88—bTl#!"(;ϰ.PX|Qʆ|ͧ[5}7Y$sE*>S"װTsӋM8z183a0aQƕkEY=Ý=H')yYjGaunvxu+dòVI#=S3-;`2A();sKqH`VUpw_ϗy ;jz9hv" Y˞otGi)ʿ*W>Zt-74 H;7WafP]'n/K5YA n0 "V]4=iz:nyu8E~|"c#7oUQ,oW'r%IkאS*.\nQV#{>&.߁Mj$lM2<\x],X}㵾i9fHK=`ifJ8#=)uMBx Z3r/.rͤQZo}^eC2hNs;Y*8qnC42v%Rkĥپ :>*l4#$c+=0{dE߿h7ӂ4ح +ڏU(|Z va҉kc^SGvk'/PiZh `.vRJ*/ӎ>wdN63zԥQ=f.* l: WVNF:'n1*QKh[J0 ))}hni2FѸPA(a>G݅vJuRlNTH+苶̾5\MV V{~;S Փ#u0t2>Gc23Km{3GA}[4^Gmw} WWb1'kac[Myl3/iHP(vs+ܑAx0֨:Z <~!p`@!gqgU!ۓޖɉb|m]y?Ra9*^s[_5|":,pV] ?$l|Q[GfMVYnpE5MVlO~+!RT`|6VXn5% UkGf:2qu0{d3tYn?"̯TV!f^{%=cdfF樞n;rdq_܈+ZUN@⹗1a䨈Դ ]pkaUH?wL(aOOyⴒ/!/P;KHܤ9(#7t*Bkf9쨘 "?M!<F4YRuaP2 ;&3Q}G"poQSMZƎPj~y +hLnv!61UOvܗ3$:X\C~N;0YE:e멫\/8'z^sv[L:νtuR[)Se3HwU77vʹlݑ.)) ]"om@ֺF;N`;5B,чT1=G{k%GRάHǽi+iesO|ɐtA)Nz &Ihvy !y5.ٚ7D oT_P۟3+&9ڼ 'mgUz4=KAg륫qA-Ml~AqAۚst$ \n 'w_"JiG5Ѥh 9wԡ`HaL~/S{%PI+Ԟϊ35-k CO[\-ܵ]BcxwMmډiIdX?te, ؽ/w?%v3Dkc\1Fa􂮺&r9V}|73Sa?$2lV& #L.n6\rȺ,&fD<\.P@9a-_Q+FXxp+1.y. 5\,Vmo~k!ީXXsr?S M6o'QfiquOEQQO,0TU 3epkZlDdeYtȒGM `ZKI6A[D0YUJX~%/ϚG-{ i xNfC'ԣ>K3@-[;*u}hl[4ýGt goNH0D#:۹G%kf[|+g4#G+-佢U5l֝Q:ǣD4߇s݆&ٺ+"u7qw)+wqWIC(-A7 +ȘVnюj~5\EDIr"LvR\{1:՜⟱V3 xaOWh_qNNwks;P6(Z$^W>!n.^*}_GJ=jC.kC%GRfM"M]ē'(Dy; l4Hbq2p ;JXYA'(異2z7թG3t7b#kxY! ͩD)֐u ҚsV{p4)J0n;.Kг 7ըv)&xIS1Rt'v*F_HZدKF܁e+6jbuq1в勣RUlptv4T2ԕk/T <v꺆t]r̭eƋ)+} 2M?O>=#fyzQ ˟S(|[: ::H3x޸}b:Գ InE sZ;* \2^ uJxS*-dv FV[;S끤 {dnH}a;Vf$G:f)RqhT>Y+Z>Hgb<4%57;_,j\HDq;DǏ#=i\7Հ_8^6Z)Ξxm.$1vnYv%%u`4:)[x _KuNvOrW1ޱOiMxL5O0Ss69I$nl==3E_JqP*B7dfN\x>@o"[d0^y&hELjA10Uh )Ah7tљŭeqyg!4>'GS8;Rް$MTS_ m%{$Bgi$ޔS0o g9%pNeRrhLf } t [~U<8vV/*EFk5uQd#-]$Leb1VB\u<19^9$<|F0<. ,S&Ca1:!W{h~]t熍P8Vzcq‹{ !F0[?~4DH9<QiO'%vu;M\NԴGRMF6;K[$,i+ݒbqeJWw/p{+-Q;7&y.tb"Hg W*rbᛇ9gt/$܍>%OAۯE OyL ee)[VoҺm;}JD R{[1*9QXsS%hKGWI#}bPK2?V"*nZ*V*Ҽ ȭͺQƊkP]Y 9F_+u<T6}kL'N!,ͥRmn.M',}gro˴GN85ʰĜ7 Mt􈽽.7w$ 6ZsV%UZZAN۞R:H| `՝;:7Ny %^6<̬#HhiNG։p̡fP=(rGAVGS RInn!Ze5X#GS3ba{͚H=MJ~e(JQFw{ξDu'ۤm>ԟHɷ/>hIݧZ \zV"V rec M\vU]V+ds6鲪 .~i\"a4YIqrNARy$fCgX@XǦB|i6;%ئ sPkHyd7SSXTZE4ٺph9uH>,I',vUc2P**[MYH#鬛7WYT{;&XY3xm5{[v9"z#6ߤ9p*z6[g|LJd*WbѹF ARں)Z.nzWdk4x 3bՅ%&^}+\ fObw DŽЎٔHrIcoJG+U('@6bN )7(r#HAO'%^_EzƶYY]G8F..Ԧ~X{]0v.A rds"^ГgѦyy-/;0S\:V%-`xi5B9dڛeV(:^g7]8^֞^4rnܩ4tS&a^VE؁t%3K0nIY%͢84)i u֨ӌ9*6xX_XAMn,> ㆽ-/PB@pa͏SWl޹#/ASQNħt!PBWЪ l?3? ;b㨈|Ѱmt gp9@S Z3vCU$J =s up~ܔ1Z bGckKad AP')]r_fsc,)׷=%T:2wj P|o*+kn;_`4THz| eu4KyR~}=Kqn!9k]XR|gr͚wہ}N]+GZ:AI7+.6MJ5I7FD*sxdUbFuǯV78^.3;>,sOr"p ]#'C>ٴ]tn8ď_}d^SI BXZ]Zg7vV}/.GrnPޮ%"j`YD0RҹܷRs;ORzC6]e:x# xN]lTv=!T_oU/0v; mu8n*26Nz/||WuWM 6rpcnyGcp۽auCڌ)ѶżH^8OnnҊm{{7^qYqwyh/.U7?Dž5n"l?<8c 6n3Y;Lpqp9/(t=y?(*VgNCeELqݞTiK% J8pwY!.zy%[:/ϽDBԞd(~։lӹs>a_WWё(tNmo"Iy%$ֺ֙w mX^j{l;jGfsn9uGU]VG('0lJ8юVy+0[ha4'v0[쟢i85fo)VhfWv%2R$,<?ʛ{fp ⒤$E,d-1U epE9o7SL%E8%Чer\ms)ެrw$ohW_&6uVhq(JSaB6^Z*..9?3}Z[M,s*O#o"ZjSvꑊSdg䈱N";2tPxΒLjY:iftZ.9F_\I"10IfVZ:3 c$]$hĮIjIV氰-mS#n1. 8:#DWG}JF9\:])]m+_; w𠣪/6c5D7@yIߪīn`UjI;""I:1vU4.kMN#;_=vq w=@_32c/OFFPv= : aݠ֢:Iy\.E騨ÇEFޒN. ک%H(ܪ[cngd{#w&x#3f6ި89x,r7r1T8A]H]ÅF插S7̔;qR{#>&v>HNq)T͈Y*% (r=lLHu >X[߂5uRIII+ =nNw4SvWs L"vrz0zvje0O1%wKncprq{z)uftYRë2eMxU.}3XU#gnGZa$-JO|gI(f#&̾#vjϒ;EB4 +N]~,ٍG7'nY^;հՆ3!V#V<>?uKb]8cddy'D4}84H*~ͷI \h-dPTg|+Me7Z]+5Ug$Fߚ_tXX}HX8!Ĕtsq~T?{oE"i{=5!k˻;uvQ+d<.mf׹SN#(KSN<.?5V9rx!},rs')9vZ\+א:_~Vy,TtO)xY]De9{*Y#xIaM(cIg u5O nL5΀24R<ɜ.IEvellMت㛲|ŕF'O=i,ڌz@czkoNhpcMc,`EZ[fu}KMRmWW4aFF kC?4TGX{-GD"F$f+end~"n\UYhLXٚ?WX&sudn a5s##81vy?"[~:v(T[uk[e&K-RwD.IU沤%We,9vݔ(=RμXj"wW4&t<ٿ4kU|lf~MʗB9kr6JDmMF^@:gԻ+F{o~g p|{o܅p ў9x"F;rTb3@8F'JE+F-J26/Y(=gXr}}ʉin$ͫno3U-?o|Pu򌧪9a}#{DｑޯvL^iInq{.,ӛ_Mﮗ81. "]~LBߊn gG8?(F/1e%[EMXFJ?NfXXxÑ~'S.M]%TcvnҦUtn-E}(Fd"ǖ訰h`l\G%,wJ''Te,csYwX#r|~J*l2S"^pGSkcTO1>lv~AmUhǕgmD8 y.utVEGLV`cMp 6?]f8{nc9V!,Y.ۼ/,\8rêA98w5[(Ǵ=;V%D\ZT3)y)*/ʋn+1GթϱH?|4Yx&Bѵvҩ%[~lTݲ륱 KHg_:kG{ԛw/To 24ߏț B;9l+ ~gndbqBbenTb(Rw"g'8ڍ\w{NAxߗ)ae xSyc oyy w~;$/%Ύ9y/*$j:fwDG^^VwD^^^|شE(^-Զ-M S|1S༼T{8UiG+ʕw/W.6nJWzz2*$-Ѿu^^^a{+7{~.ͩ\ð>^e_N,6^^Z0hP#[~Q4C7qT似fQsQ//.ʽb&MW̵=pU5*vxAyypJ;^^\V'٧$$If!vh5*#v*:V 0DyK Educate100@aol.comyK Lmailto:Educate100@aol.comyX;H,]ą'cg$$If!vh#v*:V *,5*/ 4ap yto$$If!vh#vT#v:V *,5T5/ / / / 4apyto$$If!vh#vT#v:V *,5T5/ / / / 4apyto$$If!vh#vT#v:V *,5T5/ / / / 4apyto$$If!vh#vT#v:V *,5T5/ / / / 4apyto$$If!vh#vT#v:V *,5T5/ / / / 4apyto$$If!vh#vT#v:V *,5T5/ / / / 4apyto$$If!vh#vT#v:V *,5T5/ / / / 4apyto$$If!vh#vT#v:V *,5T5/ / / / 4apyto$$If!vh#vT#v:V *,5T5/ / / / 4apytoDyK yK Jhttp://www.rnceus.com/inhal/hist.htmDyK yK Jhttp://www.rnceus.com/inhal/phys.htmDyK yK Lhttp://www.rnceus.com/inhal/psych.htmDyK yK Jhttp://www.rnceus.com/inhal/diag.htmDyK  yK Rhttp://www.rnceus.com/inhal/inmethod.htmhuffDyK  yK Rhttp://www.rnceus.com/inhal/inmethod.htmsniffS$$If!vh#v*:V 5*4-ap yt^F DyK Educate100@aol.comyK Lmailto:Educate100@aol.comyX;H,]ą'cs666666666vvvvvvvvv6666668666666666666666666666666666666666666666666666666H6666666666666666666666666666666666666666666666666666666666666666662 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@_HmH nH sH tH D`D Normal*$CJ_HaJmH sH tHZZ  Heading 1@& & F & FCJ05KHaJ0\`` !| Heading 2$<@&$56CJOJQJ\]aJmHsHZZ u Heading 4$<@&5CJOJQJ\aJmHsH^@^ `T Heading 5 <@&$56CJOJQJ\]aJmHsHDA D Default Paragraph FontVi@V 0 Table Normal :V 44 la (k ( 0No List 2/2 WW8Num2z0OJ QJ 2/2 WW8Num3z0OJ QJ 6/6 WW8Num4z0 CJOJQJ6/!6 WW8Num4z1 CJOJ QJ 6/16 WW8Num4z2 CJOJ QJ 6/A6 WW8Num5z0 CJOJQJ6/Q6 WW8Num5z1 CJOJ QJ 6/a6 WW8Num5z2 CJOJ QJ 6/q6 WW8Num6z0 CJOJQJ6/6 WW8Num6z1 CJOJ QJ 6/6 WW8Num6z2 CJOJ QJ 2/2 WW8Num7z0OJQJ6/6 WW8Num7z1 OJ QJ ^J 2/2 WW8Num7z2OJ QJ 6/6 WW8Num8z0 CJOJQJ6/6 WW8Num8z1 CJOJ QJ 6/6 WW8Num8z2 CJOJ QJ 6/6 WW8Num9z0 CJOJQJ6/6 WW8Num9z1 CJOJ QJ 6/!6 WW8Num9z2 CJOJ QJ 8/18 WW8Num10z0 OJQJ^J8/A8 WW8Num10z1 CJOJ QJ 8/Q8 WW8Num10z2 CJOJ QJ 4/a4 WW8Num11z0OJ QJ 8/q8 WW8Num11z1 OJ QJ ^J 8/8 WW8Num11z2 CJOJ QJ 4/4 WW8Num12z0OJ QJ 8/8 WW8Num12z1 OJ QJ ^J 8/8 WW8Num12z2 CJOJ QJ 8/8 WW8Num13z0 CJOJQJ8/8 WW8Num13z1 CJOJ QJ 8/8 WW8Num13z2 CJOJ QJ 4/4 WW8Num14z0OJ QJ 4/4 WW8Num15z0OJQJ8/8 WW8Num15z1 OJ QJ ^J 4/!4 WW8Num15z2OJ QJ 8/18 WW8Num16z0 CJOJQJ8/A8 WW8Num17z0 CJOJQJ8/Q8 WW8Num17z1 CJOJ QJ 8/a8 WW8Num17z2 CJOJ QJ 8/q8 WW8Num18z0 CJOJQJ8/8 WW8Num19z0 CJOJQJ8/8 WW8Num19z1 CJOJ QJ 8/8 WW8Num19z2 CJOJ QJ 8/8 WW8Num20z0 CJOJQJ8/8 WW8Num20z1 CJOJ QJ 8/8 WW8Num20z2 CJOJ QJ 8/8 WW8Num21z0 CJOJQJ8/8 WW8Num21z1 CJOJ QJ 8/8 WW8Num21z2 CJOJ QJ 8/8 WW8Num22z0 CJOJQJ8/!8 WW8Num22z1 CJOJ QJ 8/18 WW8Num22z2 CJOJ QJ 8/A8 WW8Num23z0 CJOJQJ4/Q4 WW8Num24z0OJ QJ 8/a8 WW8Num24z1 OJ QJ ^J 8/q8 WW8Num24z2 CJOJ QJ 4/4 WW8Num25z0OJ QJ 8/8 WW8Num26z0 CJOJQJ8/8 WW8Num26z1 CJOJ QJ 8/8 WW8Num26z2 CJOJ QJ J/J Absatz-Standardschriftart2/2 WW8Num1z0OJ QJ 6/6 WW8Num1z1 OJ QJ ^J 2/2 WW8Num1z3OJQJ6/6 WW8Num2z1 OJ QJ ^J 2/2 WW8Num2z3OJQJ6/!6 WW8Num3z1 OJ QJ ^J 2/12 WW8Num3z3OJQJ4/A4 WW8Num11z3OJQJ4/Q4 WW8Num12z3OJQJ8/a8 WW8Num14z1 OJ QJ ^J 4/q4 WW8Num14z3OJQJ8/8 WW8Num16z1 CJOJ QJ 8/8 WW8Num16z2 CJOJ QJ 8/8 WW8Num18z1 CJOJ QJ 8/8 WW8Num18z2 CJOJ QJ 8/8 WW8Num23z1 CJOJ QJ 8/8 WW8Num23z2 CJOJ QJ 4/4 WW8Num24z3OJQJ4/4 WW8Num25z3OJQJ8/8 WW8Num25z4 OJ QJ ^J 4/4 WW8Num27z0OJ QJ 8/!8 WW8Num27z1 OJ QJ ^J 4/14 WW8Num27z3OJQJ8/A8 WW8Num28z0 CJOJQJ8/Q8 WW8Num28z1 CJOJ QJ 8/a8 WW8Num28z2 CJOJ QJ 4/q4 WW8Num29z0OJ QJ 8/8 WW8Num29z1 OJ QJ ^J 4/4 WW8Num29z3OJQJ4/4 WW8Num30z0OJ QJ 8/8 WW8Num30z1 OJ QJ ^J 4/4 WW8Num30z3OJQJ8/8 WW8Num31z0 CJOJQJ8/8 WW8Num31z1 CJOJ QJ 8/8 WW8Num31z2 CJOJ QJ 8/8 WW8Num32z0 CJOJQJ8/8 WW8Num32z1 CJOJ QJ 8/!8 WW8Num32z2 CJOJ QJ 8/18 WW8Num33z0 CJOJQJ8/A8 WW8Num33z1 CJOJ QJ 8/Q8 WW8Num33z2 CJOJ QJ 8/a8 WW8Num34z0 CJOJQJ8/q8 WW8Num34z1 CJOJ QJ 8/8 WW8Num34z2 CJOJ QJ 8/8 WW8Num35z0 CJOJQJ8/8 WW8Num35z1 CJOJ QJ 8/8 WW8Num35z2 CJOJ QJ 8/8 WW8Num36z0 CJOJQJ8/8 WW8Num36z1 CJOJ QJ 8/8 WW8Num36z2 CJOJ QJ 4/4 WW8Num37z0OJ QJ 8/8 WW8Num37z1 OJ QJ ^J 4/4 WW8Num37z3OJQJ8/!8 WW8Num38z0 CJOJQJ8/18 WW8Num38z1 CJOJ QJ 8/A8 WW8Num38z2 CJOJ QJ 4/Q4 WW8Num39z0OJ QJ 8/a8 WW8Num39z1 OJ QJ ^J 4/q4 WW8Num39z3OJQJ8/8 WW8Num40z0 CJOJQJ8/8 WW8Num40z1 CJOJ QJ 8/8 WW8Num40z2 CJOJ QJ DA`D Default Paragraph Font6U`6 Hyperlink >*B*ph.)@. Page NumberNN Heading x$OJQJCJPJ ^JaJ6B6 Body Text x(/ ( List^JH" H Caption xx $CJ6^JaJ]." . Index $^JF^@2 F Normal (Web)  B*pht\t z-Top of Form $a$$d%d&d'd B*phOJQJCJ^JaJ<z]z z-Bottom of Form $a$$d%d&d'd B*phOJQJCJ^JaJ<<@b < 0Header !mHsH< @r < 0Footer !mHsH< < Table Contents $F F Table Heading $a$ $5\8 8 Frame contents:/ : dE0 Header Char CJaJtH:/ : dE0 Footer Char CJaJtH\/ \ !|Heading 2 Char(56CJOJPJQJ\]^JaJtHV/ V uHeading 4 Char"5CJOJPJQJ\^JaJtH\/ \ `THeading 5 Char(56CJOJPJQJ\]^JaJtH(W` ( `TStrong5PK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭VvnB`2ǃ,!"E3p#9GQd; H xuv 0F[,F᚜K sO'3w #vfSVbsؠyX p5veuw 1z@ l,i!b I jZ2|9L$Z15xl.(zm${d:\@'23œln$^-@^i?D&|#td!6lġB"&63yy@t!HjpU*yeXry3~{s:FXI O5Y[Y!}S˪.7bd|n]671. tn/w/+[t6}PsںsL. J;̊iN $AI)t2 Lmx:(}\-i*xQCJuWl'QyI@ھ m2DBAR4 w¢naQ`ԲɁ W=0#xBdT/.3-F>bYL%׭˓KK 6HhfPQ=h)GBms]_Ԡ'CZѨys v@c])h7Jهic?FS.NP$ e&\Ӏ+I "'%QÕ@c![paAV.9Hd<ӮHVX*%A{Yr Aբ pxSL9":3U5U NC(p%u@;[d`4)]t#9M4W=P5*f̰lk<_X-C wT%Ժ}B% Y,] A̠&oʰŨ; \lc`|,bUvPK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 0_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!R%theme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] Q r6646r66 $$$$$$HHHHHHHHHHHHHHHHLLlllop )FUITDbo~ p<_iD nr uD45ETIUHdii j%jSjbjr{4Qw%q)AY1 LrS|0?Dw˞ SrXXXXXXXX  )027BELdgo! !!!t ,R$oiwbp+@H 0(  (    <A#" ?6 3 rk*T%4-u1.0-B0-323-01684-7..50013-7--para1#4-u1.0-B0-323-01684-7..50013-7--p75(4-u1.0-B0-323-01684-7..50013-7--cesec1_1&4-u1.0-B0-323-01684-7..50013-7--cesec1(4-u1.0-B0-323-01684-7..50013-7--cesectit(4-u1.0-B0-323-01684-7..50014-9--cetable1ss > >JS    ps. .>>SSYY||}},}.}B}D}U}W}n}p} J]&(2?B    (-7;ps333333333333333333333333378   o o ==>>(>)>aavv~~ߣQT_cJJCI.4 %-7;JLPlops78   o o ==>>(>)>aavv~~ߣQT_cJJCI.4 %-7;JLPloos      l: zX (!lbo3+k>m NMv P^`P@^@`0^`0`^``^`^`^``^``0^0`^`OJ QJ ^`OJ QJ  ^`OJQJCJ ^`OJ QJ CJo pp^p`OJ QJ CJ @ @ ^@ `OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ PP^P`OJ QJ CJ ^`OJQJCJ ^`OJ QJ CJo pp^p`OJ QJ CJ @ @ ^@ `OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ PP^P`OJ QJ CJ ^`OJQJCJ ^`OJ QJ CJo pp^p`OJ QJ CJ @ @ ^@ `OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ PP^P`OJ QJ CJ^`OJQJ ^`OJ QJ ^J opp^p`OJ QJ @ @ ^@ `OJ QJ ^`OJ QJ ^`OJ QJ ^`OJ QJ ^`OJ QJ PP^P`OJ QJ  ^`OJQJCJ ^`OJ QJ CJo pp^p`OJ QJ CJ @ @ ^@ `OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ PP^P`OJ QJ CJ ^`OJQJCJ ^`OJ QJ CJo pp^p`OJ QJ CJ @ @ ^@ `OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ PP^P`OJ QJ CJ ^`OJQJ^J ^`OJ QJ CJo pp^p`OJ QJ CJ @ @ ^@ `OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ PP^P`OJ QJ CJ^`OJQJ ^`OJ QJ ^J o pp^p`OJ QJ CJ @ @ ^@ `OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ PP^P`OJ QJ CJ^`OJQJ ^`OJ QJ ^J o pp^p`OJ QJ CJ @ @ ^@ `OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ PP^P`OJ QJ CJ ^`OJQJCJ ^`OJ QJ CJo pp^p`OJ QJ CJ @ @ ^@ `OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ PP^P`OJ QJ CJ^`OJ QJ M^`OJQJ ^`OJ QJ ^J opp^p`OJ QJ @ @ ^@ `OJ QJ ^`OJ QJ ^`OJ QJ ^`OJ QJ ^`OJ QJ PP^P`OJ QJ  ^`OJ QJ CJ ^`OJQJCJ ^`OJ QJ CJo pp^p`OJ QJ CJ @ @ ^@ `OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ PP^P`OJ QJ CJ ^`OJ QJ CJ ^`OJQJCJ ^`OJ QJ CJo pp^p`OJ QJ CJ @ @ ^@ `OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ PP^P`OJ QJ CJ ^`OJQJCJ ^`OJ QJ CJo pp^p`OJ QJ CJ @ @ ^@ `OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ PP^P`OJ QJ CJ ^`OJQJCJ ^`OJ QJ CJo pp^p`OJ QJ CJ @ @ ^@ `OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ PP^P`OJ QJ CJ ^`OJQJCJ ^`OJ QJ CJo pp^p`OJ QJ CJ @ @ ^@ `OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ PP^P`OJ QJ CJ ^`OJ QJ CJM^`OJQJ ^`OJ QJ ^J o pp^p`OJ QJ CJ @ @ ^@ `OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ PP^P`OJ QJ CJ^`OJ QJ L ^`OJQJCJ ^`OJ QJ CJo pp^p`OJ QJ CJ @ @ ^@ `OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ ^`OJ QJ CJ PP^P`OJ QJ CJ^`o(.h   ^ `o(hH.  L ^ `LhH. xx^x`hH. HH^H`hH. L^`LhH. ^`hH. ^`hH. L^`LhH.hh^h`o(.hp^p`OJ QJ o(hHMh@ ^@ `OJ QJ ^J o(hHoh^`OJ QJ o(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJ QJ o(hHhP^P`OJQJo(hHh ^ `OJ QJ ^J o(hHoh^`OJ QJ o(hHh8^8`OJ QJ Mh^`OJ QJ ^J o(hHoh ^ `OJ QJ o(hHh ^ `OJQJo(hHhx^x`OJ QJ ^J o(hHohH^H`OJ QJ o(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJ QJ o(hH^`CJOJQJo(^`CJOJ QJ o(opp^p`CJOJ QJ o(@ @ ^@ `CJOJ QJ o(^`CJOJ QJ o(^`CJOJ QJ o(^`CJOJ QJ o(^`CJOJ QJ o(PP^P`CJOJ QJ o(^`o(.  (!lb+kzXMv>ml WW8Num2WW8Num3WW8Num4WW8Num5WW8Num6WW8Num7WW8Num8WW8Num9WW8Num10WW8Num11WW8Num12WW8Num13WW8Num14WW8Num15WW8Num16WW8Num17WW8Num18WW8Num19WW8Num20WW8Num21WW8Num22WW8Num23WW8Num24WW8Num25WW8Num26 .(                        10CSN8W!|^F dE/v,-.g@/R69&6;<'TyTW]L]Jg$lAur_L`dp!+#8-W# K D Cdp uo@/7`T#*}@JJJJr@Unknown G*Ax Times New Roman5Symbol3. *Cx Arial5. .[`)TahomaA. Trebuchet MSA. Arial Narrow7. [ @Verdana7@Cambria7.@Calibri;Wingdings?= *Cx Courier NewO.  k9Lucida Sans UnicodeA$BCambria Math"hGG f''!0 JCRP o! xx $Inhalant Abuse: Nursing Implications Tami Espejo TERRY-HOME                           Oh+'0 $ D P \ ht|(Inhalant Abuse: Nursing Implications Tami EspejoNormal TERRY-HOME2Microsoft Office Word@F#@6٧@p7@p7'՜.+,D՜.+,T hp  Toshiba %Inhalant Abuse: Nursing Implications Title< 8@ _PID_HLINKSA0V(mailto:Educate100@aol.com )http://www.rnceus.com/inhal/inmethod.htmsniff)http://www.rnceus.com/inhal/inmethod.htmhuff  %http://www.rnceus.com/inhal/diag.htmBK &http://www.rnceus.com/inhal/psych.htm%http://www.rnceus.com/inhal/phys.htm %http://www.rnceus.com/inhal/hist.htmV(mailto:Educate100@aol.com  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./023456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxz{|}~Root Entry FP;@Data _1Table1ˏWordDocumentSummaryInformation(yDocumentSummaryInformation8CompObjr  F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q